137 results on '"Nonhodgkin lymphoma"'
Search Results
2. A Study of Evorpacept (ALX148) in Patients With Advanced Solid Tumors and Lymphoma (ASPEN-01)
- Published
- 2024
3. Testicular diffuse large B-cell lymphoma. Clinical lecture and case report
- Author
-
K. B. Lelyavin, A. V. Taranenko, and V. G. Bryukhanov
- Subjects
diffuse large b-cell lymphoma ,primary testicular lymphoma ,nonhodgkin lymphoma ,Science - Abstract
Lymphoma is a heterogeneous group of lymphocyte malignancies that may involve lymphatic tissue, bone marrow, or extranodal sites. The lecture provides a brief overview of the current state of the problem of diagnosis and treatment of primary testicular lymphoma. Primary testicular lymphoma (PTL) is a rare lymphoid malignancy. Though it is rare, PTL is the most common type of testicular tumor in men over 60 years of age. The most common histological type is diffuse large B-cell lymphoma. To date, there are no well-documented etiological or risk factors for PTL. In contrast to other common testicular neoplasms, there was no statistically significant association of PTL with cryptorchidism, trauma, chronic orchitis, or infertility. Ultrasound is generally the first-line imaging method used to characterize testicular lesions. PTL manifests itself in the form of a hypoechoic formation, which can take the form of either a single large formation or multiple small formations that occupy most of the testicular parenchyma or completely replace it. Systemic treatment, including orchiectomy, chemotherapy, radiation therapy, and intrathecal prophylaxis, is necessary for all patients with PTL. In addition to achieving complete remission, the goal of PTL treatment is to prevent recurrences in the contralateral testis and central nervous system. The presented information is supplemented by our own observation and images. Personal medical data is published with the written consent of the patient. In our case, the patient’s age was 38 years, which does not fall into the specified age group for primary testicular lymphoma. In our opinion, the publication of this clinical case and analysis of scientific literature on this topic are relevant.
- Published
- 2023
- Full Text
- View/download PDF
4. Nivolumab With Epstein Barr Virus Specific T Cells (EBVSTS), Relapsed/Refractory EBV Positive Lymphoma (PREVALE) (PREVALE)
- Author
-
The Methodist Hospital Research Institute, Center for Cell and Gene Therapy, Baylor College of Medicine, and Helen Heslop, Director CAGT
- Published
- 2021
5. A Dose Finding Study Followed by a Safety and Efficacy Study for Patients With Multiple Myeloma or Lymphoma
- Published
- 2021
6. HORIZONS: Understanding the Impact of Cancer Diagnosis and Treatment on Everyday Life
- Author
-
University of Southampton
- Published
- 2021
7. Primary Bone Marrow Lymphoma with Secondary Central Nervous System Involvement: A Case Report.
- Author
-
PRIYA, R. HARI, SUZANA, A. ALIA, HAFIZA, A., RAHAYU, M. Z. REENA, RAFEAH, T. NOR, SIVAKUMAR, P., and AZMA, R. S. RAJA ZAHRATUL
- Subjects
- *
METASTASIS ,BONE marrow cancer ,CENTRAL nervous system tumors - Abstract
Primary bone marrow lymphoma (PBML) is a rare condition. Most PBMLs are B-cell non-Hodgkin lymphomas (NHLs), where predominated by the diffuse large B-cell lymphomas (DLBCLs). Non-Hodgkin lymphomas affects extranodal sites in one-third of cases. Secondary central nervous system lymphoma (SCNSL) is a rare state which is defined as secondary central nervous system (CNS) involvement in patients with systemic lymphoma. In this report, we described a case of primary bone marrow lymphoma with secondary involvement of the CNS. Patient presented with neurological deficit. Peripheral blood film showed presence of abnormal mononuclear cells. Histopathological examination of the brain tissue showed features of DLBCL with CD10 positivity. Bone marrow examination showed presence of lymphoma cells. He was commenced with Rituximab, methotrexate, vincristine and procarbazine (R-MPV). However, he succumbed after two cycles of chemotherapy. [ABSTRACT FROM AUTHOR]
- Published
- 2022
- Full Text
- View/download PDF
8. Assessment of neutrophil/lymphocyte ratio in relation to presentation and prognosis of diffuse large B-cell nonhodgkin lymphoma
- Author
-
Waseem F Al-Tameemi and Ahmed Jaber Mahmmood
- Subjects
lymphocyte ,neutrophil ,nonhodgkin lymphoma ,prognosis ,Diseases of the circulatory (Cardiovascular) system ,RC666-701 - Abstract
BACKGROUND: Diffuse large B-cell lymphoma (DLBCL) is representing 30%–40% of all lymphomas. It is an aggressive lymphoma with heterogeneous clinicopathological features. Inflammatory processes have been identified to play an important role in the pathogenesis of lymphoma including the neutrophil-lymphocyte ratio (NL ratio) was associated with a poor prognosis. AIM OF STUDY: The aim of this study is to assess neutrophil/lymphocyte (N/L) ratio in relation to clinical presentation, and other prognosticators in DLBCL, and to study the effect of these markers with response rate and early outcome. PATIENTS AND METHODS: This is a cohort prospective study with data obtained from May 2018 to November 2019. Data collected from multiple hematological centers in Baghdad, Iraq. A total of 58 adult patients who are newly diagnosed with DLBCL were enrolled. In addition to demographic features, international prognostic index (IPI) score, complete blood parameters (white blood cell count, N/L ratio, had assessed. RESULTS: The mean age was 53.54 ± 14.95 years. Twenty-two (45.83%) had extranodal involvement at the presentation. Advanced stage was reported in 34 (70.83%). Median N/L ratio was 3.39 with cut-off values 4.41. There was no significant association with the N/L ratio neither with progression-free survival (PFS) nor with the advanced stage presentation (P = 0.238, 0.343, respectively). It is found also that higher median N/L ratio was significantly associated with high and high-intermediate IPI score (P = 0.03). CONCLUSION: The NL ratio has a significant association with the IPI score, but not with the disease PFS.
- Published
- 2021
- Full Text
- View/download PDF
9. Radiation Dose Optimization in Diffuse Large B- Cell Lymphoma. (DOBL)
- Author
-
Jayant Sastri Goda, Associate Professor
- Published
- 2017
10. Non-kutanöz Periferik T-hücreli Lenfomalarda Klinik Özellikler ve Tedavi Sonuçlarına ilişkin Gerçek Yaşam Deneyimi:Türk Hematoloji Araştırma ve Eğitim Grubunun Çok Merkezli Çalışması
- Author
-
Gündüz, Mehmet, Kayıkçı, Ömür, Büyükaşık, Yahya, Eser, Bülent, Mehtap, Özgür, Sarı, İsmail, Demirkan, Fatih, Beyan, Cengiz, Vural, Filiz, Yılmaz, Mehmet, Öztürk, Erman, Akpınar, Seval, Çetin, GÜVEN, Tekgündüz, Emre, Kelkitli, Engin, Özkan, Atilla, Doğu, Mehmet Hilmi, Yıldırım, Rahşan, Payzın, Bahriye, Tıp Fakültesi, İstinye Üniversitesi, Tıp Fakültesi, Dahili Tıp Bilimleri Bölümü, Yıldırım, Rahşan, Mehmet Hilmi Doğu / W-2255-2017, Rahşan Yıldırım / GKE-1453-2022, Rahşan Yıldırım / 23988125700, and ÇETİN, GÜVEN
- Subjects
cancer patient ,autologous stem cell transplantation ,positron emission tomography ,Survival ,retrospective study ,Lenfomalar ,pelvis ,Autologous stem cell transplantation ,physical examination ,computer assisted tomography ,Non Cutaneous Peripheral T Cell Lymphoma ,Antineoplastic Combined Chemotherapy Protocols ,Disease ,salvage therapy ,cancer survival ,antineoplastic agent ,Non-Hodgkin lymphoma ,thorax ,progression free survival ,nonhodgkin lymphoma ,hematology ,adult ,Hematopoietic Stem Cell Transplantation ,Cohort ,clinical trial ,Hematology ,anaplastic lymphoma kinase ,lymph node ,Prognosis ,International Prognostic Index ,fluorodeoxyglucose f 18 ,bone marrow biopsy ,female ,Treatment Outcome ,risk factor ,anaplastic large cell lymphoma ,Lymphomas ,overall survival ,peripheral T cell lymphoma ,Up-Front ,overall response rate ,Otolog Kök Hücre Nakli ,Guidelines ,cancer prognosis ,Transplantation, Autologous ,Article ,hematopoietic cell ,remission ,male ,autologous hematopoietic stem cell transplantation ,Humans ,biopsy ,liver function test ,human ,procedures ,T-cell lymphomas ,Retrospective Studies ,Transplantation ,autotransplantation ,Non-Hodgkin Lenfoma ,High-Dose Chemotherapy ,Lymphoma, T-Cell, Peripheral ,T-Hücreli Lenfomalar ,neck ,A Multicenter Study of Turkish Hematology Research and Education Group (Threg).-, Turkish journal of haematology : official journal of Turkish Society of Haematology, 2022 [Kayıkçı Ö., Mehtap Ö., Sarı İ., Demirkan F., Beyan C., Çetin G., Vural F., Yılmaz M., Öztürk E., Akpınar S., et al., -Real Life Experience Regarding Clinical Characteristics and Treatment Outcome in Non-Cutaneous Peripheral T Cell Lymphomas] ,human tissue ,multicenter study ,American Society ,pathology ,abdomen ,transplantation - Abstract
Objective: Peripheral T-cell lymphomas (PTCLs) are an uncommon and quite heterogeneous group of disorders, representing only 10%-15% of all non-Hodgkin lymphomas. Although both molecular and clinical studies have increased in recent years, we still have little knowledge regarding real-life practice with PTCLs. In this study, we aimed to investigate the clinical characteristics and treatment outcomes of a large population-based cohort of patients presenting with systemic non-cutaneous PTCL. Materials and Methods: We conducted a multicenter retrospective analysis of 190 patients consecutively diagnosed and treated with non-cutaneous PTCLs between 2008 and 2016. Results: Considering all first-line treatment combinations, the overall response rate was 65.9% with 49.4% complete remission (n=81) and 16.5% partial response (n=27). The 5-year overall survival and eventfree survival rates were significantly different between the transplant and non-transplant groups (p, Amaç: Periferik T-hücreli lenfomalar (PTHL) nadir görülen, oldukça heterojen bir grup hastalıktır ve tüm non-Hodgkin lenfomaların sadece %10-15’ini oluşturur. Son yıllarda hem moleküler hem de klinik çalışmalar artmış olsa da PTHL’ler üzerindeki gerçek yaşam verileri hakkında hala çok az bilgiye sahibiz. Bu çalışmada, sistemik, kutanöz olmayan PTHL hastaları içeren geniş popülasyon tabanlı hasta grubunun klinik özellikleri ve tedavi sonuçlarını araştırmayı amaçladık. Gereç ve Yöntemler: 2008 ve 2016 yılları arasında kutanöz olmayan PTHL tanısı ile tedavi edilen 190 ardışık hastanın geriye dönük analizini gerçekleştirdik. Bulgular: Tüm birinci basamak tedavi kombinasyonları dikkate alındığında, genel yanıt oranı; tam remisyon (n=81) %49,4 ve kısmi yanıt (n=27) %16,5 olmak üzere %65,9 saptandı. Beş yıllık genel ve olaysız sağkalım oranları, transplant ve transplant olmayan gruplar arasında önemli ölçüde farklıydı (sırasıyla, p
- Published
- 2022
11. Granulomatosis after autologous stem cell transplantation in nonHodgkin lymphoma – experience of single institution and a review of literature
- Author
-
Boltezar Lucka, Zagar Ivana, and Novakovic Barbara Jezersek
- Subjects
granulomatosis ,nonhodgkin lymphoma ,pet-ct ,differential diagnosis ,tissue biopsy ,Medical physics. Medical radiology. Nuclear medicine ,R895-920 - Abstract
Sarcoidosis before and after treatment of malignancy is an important differential diagnosis that has to be distinguished from lymphoma.
- Published
- 2016
- Full Text
- View/download PDF
12. HEDEFE YÖNELİK TEDAVİDE GÜNCEL YAKLAŞIMLAR: LUTESYUM-177 İLE İŞARETLİ RADYOFARMASÖTİKLER
- Author
-
Hişir D., Ekinci M., and Ilem-Özdemir D.
- Subjects
theranostic nanomedicine ,adenocarcinoma ,nonhodgkin lymphoma ,drug half life ,Review ,prostate cancer ,liver cancer ,Theranostic ,Radionuclide ,Radiopharmaceutical ,human ,nuclear medicine ,Lutetium-177 ,lutetium 177 ,neuroendocrine tumor - Abstract
Objective: In recent years, thanks to advances in targeted radionuclide therapy, significant advances have been made in the early diagnosis and treatment of diseases. With the emergence of the concept of "theranostic", which combines diagnosis and treatment methods, Lutetium-177 (Lu-177) has gained an important place in targeted therapy and has become a leading compound in this field. In this review, it is aimed to explain the basic information about radiopharmaceuticals, targeted therapy, theranostics and Lu-177, to present 177Lu-labeled molecular carriers and 177Lu-labeled radiopharmaceuticals and to review the studies on these subjects. Result and Discussion: 177Lu is a theranostic agent with a half-life of 6.7 days, which can be used in diagnosis and treatment in nuclear medicine thanks to its ? and ? rays. Its high specific activity and easy access to these activity levels as well as its relatively long half-life can be considered as the main factors of interest in the clinical use of this radionuclide. The clinical utility of 177Lu, a preferred radioisotope for targeted radionuclide therapy, in the treatment of neuroendocrine tumors, prostate cancer, non-Hodgkin lymphoma, adenocarcinoma, and liver cancer, and in alleviating bone pain, was investigated, and as a result, 177Lu was found to show great potential in cancer and pain therapy. With these areas of use, we believe that Lu-177 will have an important place in the field of nuclear medicine in the future. © 2022 University of Ankara. All rights reserved.
- Published
- 2022
13. Unusually aggressive primary testicular diffuse large B-cell lymphoma initially presenting as systemic disseminating metastases in older adult men: a case report.
- Author
-
Liu KT, Chang YC, Lin YC, and Chang JL
- Abstract
Primary testicular lymphoma (PTL) accounts for 1-2% of all nonHodgkin lymphomas (NHL), 4% of extranodal nonHodgkin lymphomas, and ~9% of testicular malignancies. A rare subtype of PTL is primary testicular diffuse large B-cell lymphoma (PT-DLBCL), which may initially present as disseminating metastasis in older adult males and has a poor prognosis., Case Presentation: Herein, the authors describe the case of a 64-year-old man with the chief complaint of a painless unilateral scrotal mass. Computed tomography scans of the abdomen and a pelvic examination demonstrated a left testicular tumor with multiple lymphadenopathies partially aggregated in the para-aortic area and disseminated to multiple soft tissues and organs. Subsequently, the patient underwent a left radical orchiectomy. Pathological and immunohistochemical examinations confirmed the diagnosis of left PT-DLBCL with systemic disseminating metastases., Clinical Discussion: PTL often aggressively spreads to other extranodal organs, such as the contralateral testis, central nervous system, lung, pleura, Waldeyer's ring, and soft tissues. In men over 60 years of age, PT-DLBCL is the most common testicular malignancy. However, extensive systemic metastasis as the initial presentation is extremely rare. PT-DLBCL has a dismal prognosis and requires radical orchiectomy followed by multimodal therapy and central nervous system prophylaxis or systemic intervention to improve survival., Conclusion: The diagnosis of PT-DLBCL through preoperative and imaging examinations is often challenging. Thus, histopathology and immunohistochemical markers play a crucial and valuable role in the definite diagnosis and differential diagnosis of PTLs., Competing Interests: The authors have no conflicts of interest to declare., (Copyright © 2023 The Author(s). Published by Wolters Kluwer Health, Inc.)
- Published
- 2023
- Full Text
- View/download PDF
14. Geographical Distribution, Incidence, Malignancies, and Outcome of 136 Eastern Slavic Patients With Nijmegen Breakage Syndrome and NBN Founder Variant c.657_661del5
- Abstract
Nijmegen breakage syndrome (NBS) is a DNA repair disorder characterized by combined immunodeficiency and a high predisposition to lymphoid malignancies. The majority of NBS patients are identified with a homozygous five base pair deletion in the Nibrin (NBN) gene (c.657_661del5, p.K219fsX19) with a founder effect observed in Caucasian European populations, especially of Slavic origin. We present here an analysis of a cohort of 136 NBS patients of Eastern Slav origin across Belarus, Ukraine, Russia, and Latvia with a focus on understanding the geographic distribution, incidence of malignancy, and treatment outcomes of this cohort. Our analysis shows that Belarus had the highest prevalence of NBS (2.3 per 1,000,000), followed by Ukraine (1.3 per 1,000,000), and Russia (0.7 per 1,000,000). Of note, the highest concentration of NBS cases was observed in the western regions of Belarus and Ukraine, where NBS prevalence exceeds 20 cases per 1,000,000 people, suggesting the presence of an “Eastern Slavic NBS hot spot.” The median age at diagnosis of this cohort ranged from 4 to 5 years, and delay in diagnosis was more pervasive in smaller cities and rural regions. A total of 62 (45%) patients developed malignancies, more commonly in males than females (55.2 vs. 34.2%; p=0.017). In 27 patients, NBS was diagnosed following the onset of malignancies (mean age: 8 years). Malignancies were mostly of lymphoid origin and predominantly non-Hodgkin lymphoma (NHL) (n=42, 68%); 38% of patients had diffuse large B-cell lymphoma. The 20-year overall survival rate of patients with malignancy was 24%. However, females with cancer experienced poorer event-free survival rates than males (16.6% vs. 46.8%, p=0.036). Of 136 NBS patients, 13 underwent hematopoietic stem cell transplantation (HSCT) with an overall survival of 3.5 years following treatment (range: 1 to 14 years). Indications for HSCT included malignancy (n=7) and immunodeficiency (n=6). Overall, 9% of patients in this cohort reac
- Published
- 2021
15. The clinicopathologic features and response to treatment of patients with Nonhodgkin Lymphoma: A single-center experiment in Turkey
- Author
-
Yildirim, Rahsan and Sincan, Gulden
- Subjects
Laboratory findings ,hemic and lymphatic diseases ,Nonhodgkin lymphoma ,Response to treatment ,Original Article - Abstract
Objective: We aimed to compare laboratory features, histopathological types, response to treatment of patients with non hodgkin lymphoma in our department and other regions. Methods: A total of 80 patients nonhodgkin lymphoma were evaluated. Because we had only 80 patients with complete data, we used T test for comparison of groups. We evaluated the parameters affecting surveillance with cox regression analysis. Results: The most common histological types of nonhodgkins lymphoma was diffuse large b cell lymphoma (n: 63, 78.75%). Thirty-nine percent of all patients had anemia, 32% had hypoalbunemia, 71.25% had elevated serum LDH, 32.5% had elevated serum ß2 microglobulin value. Advanced age, the presence of bulky disease, elevated Ki-67 level, IPI score, refractory to first line treatment were found to be correlated with shorter survival time. We treated 77 (96.25%) patients with doxorubicin containing regimen. Complete and partial remission rates of first line treatment were 77.5% and 10%, respectively. Seven (8.75%) patients died because of disease progression and 1 (1.25%) patient died due to sepsis. Conclusion: The frequency of lymphoma subtypes, clinical characteristics, treatment outcomes and survival rate vary from region to region. Therefore it is important to determine dissimilarity of these parameters for improve of survey.
- Published
- 2019
16. Geographical Distribution, Incidence, Malignancies, and Outcome of 136 Eastern Slavic Patients With Nijmegen Breakage Syndrome and NBN Founder Variant c.657_661del5
- Author
-
Ihor Savchak, Irina A. Tuzankina, E.A. Latysheva, Halyna Makukh, Anastasiia Bondarenko, Mikhail Belevtsev, Inga S. Sakovich, Elena I. Golovataya, Svetlana A. Kulyova, Larysa Kostyuchenko, Jolan E. Walter, Alexander Popa, Dzmitry S. Varabyou, Natalia V. Rumiantseva, Mei-Sing Ong, Alexander G. Beznoshchenko, Svetlana S. Vakhlyarskaya, Mark Ballow, Ekaterina A. Polyakova, Olga E. Pashchenko, Olga Aleinikova, Yuliya Mareika, Svetlana Aleshkevich, Elena V. Vlasova, Olena Kozlova, Svetlana O. Sharapova, Irina V. Naumchik, Nina V. Minakovskaya, Hayane Akopyan, Timur T. Valiev, Alina Fedorova, Tatjana Prokofjeva, Tatiana V. Latysheva, and Irina Kondratenko
- Subjects
0301 basic medicine ,Pediatrics ,GEOGRAPHIC DISTRIBUTION ,medicine.medical_treatment ,NONHODGKIN LYMPHOMA ,LYMPHOPROLIFERATIVE DISORDERS ,EASTERN EUROPE ,Hematopoietic stem cell transplantation ,MAJOR CLINICAL STUDY ,ADOLESCENT ,lymphomas, risk of malignancies ,IMMUNOLOGY ,Nijmegen breakage syndrome (NBS) ,NUCLEAR PROTEIN ,0302 clinical medicine ,CHILD ,EVENT FREE SURVIVAL ,RETROSPECTIVE STUDIES ,RETROSPECTIVE STUDY ,NBN PROTEIN, HUMAN ,Immunology and Allergy ,LYMPHOMAS, RISK OF MALIGNANCIES ,COGNITIVE DEFECT ,EPIDEMIOLOGY ,FOUNDER VARIANTS ,geographical location ,Family history ,incidence in East Slavs ,Immunodeficiency ,MALIGNANT NEOPLASM ,Incidence (epidemiology) ,HUMAN ,ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION ,HEALTH CARE SURVEY ,HEMATOPOIETIC STEM CELL TRANSPLANTATION ,CLINICAL TRIAL ,HUMANS ,INCIDENCE IN EAST SLAVS ,HEMATOLOGIC NEOPLASMS ,FOUNDER EFFECT ,FEMALE ,LYMPHOPROLIFERATIVE DISEASE ,PREVALENCE ,SOCIAL ADAPTATION ,IMMUNE DEFICIENCY ,FOLLOW UP ,MENTAL HEALTH ,Cohort ,HEMATOLOGIC DISEASE ,B CELL LYMPHOMA ,CANCER SURVIVAL ,HODGKIN DISEASE ,lcsh:Immunologic diseases. Allergy ,medicine.medical_specialty ,NIJMEGEN BREAKAGE SYNDROME ,GENETICS ,Genetic counseling ,Immunology ,COHORT ANALYSIS ,CELL CYCLE PROTEINS ,Malignancy ,founder variants ,03 medical and health sciences ,NIJMEGEN BREAKAGE SYNDROME (NBS) ,QUALITY OF LIFE ,ADULT ,GEOGRAPHICAL LOCATION ,medicine ,ARTICLE ,CELL CYCLE PROTEIN ,CHILD, PRESCHOOL ,FOLLOW-UP STUDIES ,MALE ,business.industry ,MORTALITY ,ACUTE LYMPHOBLASTIC LEUKEMIA ,social adaptation ,medicine.disease ,NIBRIN ,030104 developmental biology ,BURKITT LYMPHOMA ,OVERALL SURVIVAL ,PRESCHOOL CHILD ,NUCLEAR PROTEINS ,MULTICENTER STUDY ,INFANT ,EUROPE, EASTERN ,business ,lcsh:RC581-607 ,Nijmegen breakage syndrome ,030215 immunology ,INCIDENCE - Abstract
Nijmegen breakage syndrome (NBS) is a DNA repair disorder characterized by combined immunodeficiency and a high predisposition to lymphoid malignancies. The majority of NBS patients are identified with a homozygous five base pair deletion in the Nibrin (NBN) gene (c.657_661del5, p.K219fsX19) with a founder effect observed in Caucasian European populations, especially of Slavic origin. We present here an analysis of a cohort of 136 NBS patients of Eastern Slav origin across Belarus, Ukraine, Russia, and Latvia with a focus on understanding the geographic distribution, incidence of malignancy, and treatment outcomes of this cohort. Our analysis shows that Belarus had the highest prevalence of NBS (2.3 per 1,000,000), followed by Ukraine (1.3 per 1,000,000), and Russia (0.7 per 1,000,000). Of note, the highest concentration of NBS cases was observed in the western regions of Belarus and Ukraine, where NBS prevalence exceeds 20 cases per 1,000,000 people, suggesting the presence of an “Eastern Slavic NBS hot spot.” The median age at diagnosis of this cohort ranged from 4 to 5 years, and delay in diagnosis was more pervasive in smaller cities and rural regions. A total of 62 (45%) patients developed malignancies, more commonly in males than females (55.2 vs. 34.2%; p=0.017). In 27 patients, NBS was diagnosed following the onset of malignancies (mean age: 8 years). Malignancies were mostly of lymphoid origin and predominantly non-Hodgkin lymphoma (NHL) (n=42, 68%); 38% of patients had diffuse large B-cell lymphoma. The 20-year overall survival rate of patients with malignancy was 24%. However, females with cancer experienced poorer event-free survival rates than males (16.6% vs. 46.8%, p=0.036). Of 136 NBS patients, 13 underwent hematopoietic stem cell transplantation (HSCT) with an overall survival of 3.5 years following treatment (range: 1 to 14 years). Indications for HSCT included malignancy (n=7) and immunodeficiency (n=6). Overall, 9% of patients in this cohort reached adulthood. Adult survivors reported diminished quality of life with significant physical and cognitive impairments. Our study highlights the need to improve timely diagnosis and clinical management of NBS among Eastern Slavs. Genetic counseling and screening should be offered to individuals with a family history of NBS, especially in hot spot regions. © Copyright © 2021 Sharapova, Pashchenko, Bondarenko, Vakhlyarskaya, Prokofjeva, Fedorova, Savchak, Mareika, Valiev, Popa, Tuzankina, Vlasova, Sakovich, Polyakova, Rumiantseva, Naumchik, Kulyova, Aleshkevich, Golovataya, Minakovskaya, Belevtsev, Latysheva, Latysheva, Beznoshchenko, Akopyan, Makukh, Kozlova, Varabyou, Ballow, Ong, Walter, Kondratenko, Kostyuchenko and Aleinikova. We thank all doctors for clinical help for patients. We also appreciate the support of patient and their parents for agreeing to take part in this study. TP thanks Sergey?Nikulshin, Marika Grutupa, and Zanna Kovalova. We thank Joseph Dasso for editing this manuscript, primarily for proper English.
- Published
- 2021
17. A novel CDK9 inhibitor increases the efficacy of venetoclax (ABT-199) in multiple models of hematologic malignancies.
- Abstract
MCL-1 is one of the most frequently amplified genes in cancer, facilitating tumor initiation and maintenance and enabling resistance to anti-tumorigenic agents including the BCL-2 selective inhibitor venetoclax. The expression of MCL-1 is maintained via P-TEFb-mediated transcription, where the kinase CDK9 is a critical component. Consequently, we developed a series of potent small-molecule inhibitors of CDK9, exemplified by the orally active A-1592668, with CDK selectivity profiles that are distinct from related molecules that have been extensively studied clinically. Short-term treatment with A-1592668 rapidly downregulates RNA pol-II (Ser 2) phosphorylation resulting in the loss of MCL-1 protein and apoptosis in MCL-1-dependent hematologic tumor cell lines. This cell death could be attenuated by either inhibiting caspases or overexpressing BCL-2 protein. Synergistic cell killing was also observed between A-1592668 or the related analog A-1467729, and venetoclax in a number of hematologic cell lines and primary NHL patient samples. Importantly, the CDK9 inhibitor plus venetoclax combination was well tolerated in vivo and demonstrated efficacy superior to either agent alone in mouse models of lymphoma and AML. These data indicate that CDK9 inhibitors could be highly efficacious in tumors that depend on MCL-1 for survival or when used in combination with venetoclax in malignancies dependent on MCL-1 and BCL-2.Copyright © 2019, The Author(s).
- Published
- 2020
18. Differences in cancer survival by area-level socio-economic disadvantage: A populationbased study using cancer registry data.
- Abstract
Despite overall improvements in cancer survival due to earlier diagnosis and better treatment, socio-economically disadvantaged people have lower cancer survival than more advantaged people. We aimed to examine differences in cancer survival by area-level socio-economic disadvantage in Victoria, Australia and assess whether these inequalities varied by year of diagnosis, age at diagnosis, time since diagnosis and sex. Cases diagnosed with a first primary cancer in 2001-2015 were identified using the Victorian Cancer Registry and followed to the end of 2016. Five-year net survival and the excess risk of death due to a cancer diagnosis were estimated. People living in more disadvantaged areas had lower five-year survival than residents of less disadvantaged regions for 21 of 29 cancer types: head and neck, oesophagus, stomach, colorectum, anus/anal canal, liver, gallbladder/ biliary tract, pancreas, lung, melanoma, connective/soft tissue, female breast, ovary, prostate, kidney, bladder, brain and central nervous system, unknown primary, non-Hodgkin lymphoma, multiple myeloma and leukemia. The observed lower survival in more deprived regions persisted over time, except head and neck cancer, for which the gap in survival has widened. Socio-economic inequalities in survival decreased with increasing age at diagnosis for cancers of connective/soft tissue, bladder and unknown primary. For colorectal cancer, the observed survival disadvantage in lower socio-economic regions was greater for men than for women, while for brain and central nervous system tumours, it was larger for women. Cancer survival is generally lower for residents of more socio-economically disadvantaged areas. Identifying the underlying reasons for these inequalities is important and may help to identify effective interventions to increase survival for underprivileged cancer patients.Copyright © 2020 Afshar et al. This is an open access article distributed under the terms of the Creative Commons Attribut
- Published
- 2020
19. Linking blood use with clinical outcomes in haematologic malignancies: Pilot data from the national transfusion dataset project.
- Abstract
Aim: Patients with haematologic malignancies are major recipients of blood products; however comprehensive Australian data about clinical outcomes of transfusion are limited. As part of a feasibility study to establish a national comprehensive dataset of all transfusions and their outcomes, we analysed transfusion data for adult haematology/oncology patients from the first pilot site. Method(s): Hospital electronic data on adult patients receiving any blood product (>=1 RBC [red blood cells], platelet, FFP [fresh frozen plasma], cryoprecipitate, or plasma derivative) during 2017 were imported, linked and analysed using the expanded platform of the Australian and New Zealand Massive Transfusion Registry. Data included laboratory (for transfusion and blood tests) and hospital information systems records (for patient demographics, co-morbidities, admission and clinical outcome data). Haematology/oncology patients were identified by ICD-10-AM diagnostic codes. Analyses were performed using Stata software. Result(s): Of 5859 transfused admitted patients, 767 (13%) were haematology/ oncology patients. Of these 38% were acute leukaemias, 25% myeloma, 15% NHL (non-Hodgkin lymphoma), 7% chronic leukaemias, and 15% MDS and other haematopoietic neoplasms. Patient median age was 66.7y, [IQR, 57, 74], and 58% were male. Haematology/oncology patients were 30% (3365/11201) of all admissions where a transfusion was performed; of which 56% were day-admissions. 61% of patients were admitted only once; 34% had 2-10 admissions and 5% had 11-100 admissions. They accounted for 33% RBCs, 69% platelets, 20% cryoprecipitate, 5% FFP and 13% IVIg (intravenous immunoglobulin; in grams) transfused. For outpatients receiving platelet transfusions, median [IQR] platelet count was 17 x109/L [10, 51]. Conclusion(s): Haematology/oncology patients represented 13% of all transfused patients, but required significant proportions of the transfusion product inventory, including 69% of all platelets, cons
- Published
- 2020
20. Pneumocystis jiroveci pneumonitis in an infant.
- Abstract
ES is a 7-month-old female born to a non-consanguineous Caucasian couple at 35 weeks of gestation following a pregnancy that was complicated by Maternal Non-Hodgkin's Lymphoma requiring R-CHOP (Chemotherapy) from 17 to 35 weeks antenatally. At 12 weeks of age ES progressively deteriorated following a respiratory illness requiring invasive respiratory support. Initial investigations showed marked lymphopenia of 1.5 x 10^9/L and a search for opportunistic organisms revealed elevated Pneumocystis Jiroveci counts in her BAL. Following this she was started on a combination of Primaquine, Lincomycin and Bactrim treatment. Apart from the lymphopenia, her IgG was noted to be extremely low at <1.0 g/L. There were concerns of a primary immunodeficiency, however this was confounded by the possibility of a secondary immunodeficiency due to the use of maternal R-CHOP antenatally. Her recent thymic emigrants were noted to be 53% suggestive of adequate output from the thymus and her PHA was also normal suggestive of adequately functioning T cells. Recovery of lymphocyte counts to 7.2 x 109/L and IgG to 3.2 g/L post supportive management including intravenous immunoglobulin over the ensuing months confirmed the likelihood of a secondary immunodeficiency in her presentation. She is currently on low flow oxygen and her immunoglobulin levels have stabilized without ongoing IVIG, as her own production of immunoglobulins takes over. This case illustrates the importance of monitoring of babies born to mothers on chemotherapy and consideration of supportive management which may include antimicrobial prophylaxis and intravenous immunoglobulins during the first 6-12 months of life.
- Published
- 2020
21. A novel CDK9 inhibitor increases the efficacy of venetoclax (ABT-199) in multiple models of hematologic malignancies.
- Abstract
MCL-1 is one of the most frequently amplified genes in cancer, facilitating tumor initiation and maintenance and enabling resistance to anti-tumorigenic agents including the BCL-2 selective inhibitor venetoclax. The expression of MCL-1 is maintained via P-TEFb-mediated transcription, where the kinase CDK9 is a critical component. Consequently, we developed a series of potent small-molecule inhibitors of CDK9, exemplified by the orally active A-1592668, with CDK selectivity profiles that are distinct from related molecules that have been extensively studied clinically. Short-term treatment with A-1592668 rapidly downregulates RNA pol-II (Ser 2) phosphorylation resulting in the loss of MCL-1 protein and apoptosis in MCL-1-dependent hematologic tumor cell lines. This cell death could be attenuated by either inhibiting caspases or overexpressing BCL-2 protein. Synergistic cell killing was also observed between A-1592668 or the related analog A-1467729, and venetoclax in a number of hematologic cell lines and primary NHL patient samples. Importantly, the CDK9 inhibitor plus venetoclax combination was well tolerated in vivo and demonstrated efficacy superior to either agent alone in mouse models of lymphoma and AML. These data indicate that CDK9 inhibitors could be highly efficacious in tumors that depend on MCL-1 for survival or when used in combination with venetoclax in malignancies dependent on MCL-1 and BCL-2.Copyright © 2019, The Author(s).
- Published
- 2020
22. Differences in cancer survival by area-level socio-economic disadvantage: A populationbased study using cancer registry data.
- Abstract
Despite overall improvements in cancer survival due to earlier diagnosis and better treatment, socio-economically disadvantaged people have lower cancer survival than more advantaged people. We aimed to examine differences in cancer survival by area-level socio-economic disadvantage in Victoria, Australia and assess whether these inequalities varied by year of diagnosis, age at diagnosis, time since diagnosis and sex. Cases diagnosed with a first primary cancer in 2001-2015 were identified using the Victorian Cancer Registry and followed to the end of 2016. Five-year net survival and the excess risk of death due to a cancer diagnosis were estimated. People living in more disadvantaged areas had lower five-year survival than residents of less disadvantaged regions for 21 of 29 cancer types: head and neck, oesophagus, stomach, colorectum, anus/anal canal, liver, gallbladder/ biliary tract, pancreas, lung, melanoma, connective/soft tissue, female breast, ovary, prostate, kidney, bladder, brain and central nervous system, unknown primary, non-Hodgkin lymphoma, multiple myeloma and leukemia. The observed lower survival in more deprived regions persisted over time, except head and neck cancer, for which the gap in survival has widened. Socio-economic inequalities in survival decreased with increasing age at diagnosis for cancers of connective/soft tissue, bladder and unknown primary. For colorectal cancer, the observed survival disadvantage in lower socio-economic regions was greater for men than for women, while for brain and central nervous system tumours, it was larger for women. Cancer survival is generally lower for residents of more socio-economically disadvantaged areas. Identifying the underlying reasons for these inequalities is important and may help to identify effective interventions to increase survival for underprivileged cancer patients.Copyright © 2020 Afshar et al. This is an open access article distributed under the terms of the Creative Commons Attribut
- Published
- 2020
23. Amount and intensity of leisure-time physical activity and lower cancer risk.
- Abstract
PURPOSE To determine whether recommended amounts of leisure-time physical activity (ie, 7.5-15 metabolic equivalent task [MET] hours/week) are associated with lower cancer risk, describe the shape of the doseresponse relationship, and explore associations with moderate- and vigorous-intensity physical activity. METHODS Data from 9 prospective cohorts with self-reported leisure-time physical activity and follow-up for cancer incidence were pooled. Multivariable Cox regression was used to estimate adjusted hazard ratios (HRs) and 95% CIs of the relationships between physical activity with incidence of 15 types of cancer. Dose-response relationships were modeled with restricted cubic spline functions that compared 7.5, 15.0, 22.5, and 30.0 MET hours/week to no leisure-time physical activity, and statistically significant associations were determined using tests for trend (P <.05) and 95% CIs (<1.0). RESULTS A total of 755,459 participants (median age, 62 years [range, 32-91 years]; 53% female) were followed for 10.1 years, and 50,620 incident cancers accrued. Engagement in recommended amounts of activity (7.5-15 MET hours/week) was associated with a statistically significant lower risk of 7 of the 15 cancer types studied, including colon (8%-14% lower risk in men), breast (6%-10% lower risk), endometrial (10%-18% lower risk), kidney (11%-17% lower risk), myeloma (14%-19% lower risk), liver (18%-27% lower risk), and non-Hodgkin lymphoma (11%-18% lower risk in women). The dose response was linear in shape for half of the associations and nonlinear for the others. Results for moderate- and vigorous-intensity leisure-time physical activity were mixed. Adjustment for body mass index eliminated the association with endometrial cancer but had limited effect on other cancer types. CONCLUSION Health care providers, fitness professionals, and public health practitioners should encourage adults to adopt and maintain physical activity at recommended levels to lower risks of multip
- Published
- 2020
24. Linking blood use with clinical outcomes in haematologic malignancies: Pilot data from the national transfusion dataset project.
- Abstract
Aim: Patients with haematologic malignancies are major recipients of blood products; however comprehensive Australian data about clinical outcomes of transfusion are limited. As part of a feasibility study to establish a national comprehensive dataset of all transfusions and their outcomes, we analysed transfusion data for adult haematology/oncology patients from the first pilot site. Method(s): Hospital electronic data on adult patients receiving any blood product (>=1 RBC [red blood cells], platelet, FFP [fresh frozen plasma], cryoprecipitate, or plasma derivative) during 2017 were imported, linked and analysed using the expanded platform of the Australian and New Zealand Massive Transfusion Registry. Data included laboratory (for transfusion and blood tests) and hospital information systems records (for patient demographics, co-morbidities, admission and clinical outcome data). Haematology/oncology patients were identified by ICD-10-AM diagnostic codes. Analyses were performed using Stata software. Result(s): Of 5859 transfused admitted patients, 767 (13%) were haematology/ oncology patients. Of these 38% were acute leukaemias, 25% myeloma, 15% NHL (non-Hodgkin lymphoma), 7% chronic leukaemias, and 15% MDS and other haematopoietic neoplasms. Patient median age was 66.7y, [IQR, 57, 74], and 58% were male. Haematology/oncology patients were 30% (3365/11201) of all admissions where a transfusion was performed; of which 56% were day-admissions. 61% of patients were admitted only once; 34% had 2-10 admissions and 5% had 11-100 admissions. They accounted for 33% RBCs, 69% platelets, 20% cryoprecipitate, 5% FFP and 13% IVIg (intravenous immunoglobulin; in grams) transfused. For outpatients receiving platelet transfusions, median [IQR] platelet count was 17 x109/L [10, 51]. Conclusion(s): Haematology/oncology patients represented 13% of all transfused patients, but required significant proportions of the transfusion product inventory, including 69% of all platelets, cons
- Published
- 2020
25. Pneumocystis jiroveci pneumonitis in an infant.
- Abstract
ES is a 7-month-old female born to a non-consanguineous Caucasian couple at 35 weeks of gestation following a pregnancy that was complicated by Maternal Non-Hodgkin's Lymphoma requiring R-CHOP (Chemotherapy) from 17 to 35 weeks antenatally. At 12 weeks of age ES progressively deteriorated following a respiratory illness requiring invasive respiratory support. Initial investigations showed marked lymphopenia of 1.5 x 10^9/L and a search for opportunistic organisms revealed elevated Pneumocystis Jiroveci counts in her BAL. Following this she was started on a combination of Primaquine, Lincomycin and Bactrim treatment. Apart from the lymphopenia, her IgG was noted to be extremely low at <1.0 g/L. There were concerns of a primary immunodeficiency, however this was confounded by the possibility of a secondary immunodeficiency due to the use of maternal R-CHOP antenatally. Her recent thymic emigrants were noted to be 53% suggestive of adequate output from the thymus and her PHA was also normal suggestive of adequately functioning T cells. Recovery of lymphocyte counts to 7.2 x 109/L and IgG to 3.2 g/L post supportive management including intravenous immunoglobulin over the ensuing months confirmed the likelihood of a secondary immunodeficiency in her presentation. She is currently on low flow oxygen and her immunoglobulin levels have stabilized without ongoing IVIG, as her own production of immunoglobulins takes over. This case illustrates the importance of monitoring of babies born to mothers on chemotherapy and consideration of supportive management which may include antimicrobial prophylaxis and intravenous immunoglobulins during the first 6-12 months of life.
- Published
- 2020
26. Amount and intensity of leisure-time physical activity and lower cancer risk.
- Abstract
PURPOSE To determine whether recommended amounts of leisure-time physical activity (ie, 7.5-15 metabolic equivalent task [MET] hours/week) are associated with lower cancer risk, describe the shape of the doseresponse relationship, and explore associations with moderate- and vigorous-intensity physical activity. METHODS Data from 9 prospective cohorts with self-reported leisure-time physical activity and follow-up for cancer incidence were pooled. Multivariable Cox regression was used to estimate adjusted hazard ratios (HRs) and 95% CIs of the relationships between physical activity with incidence of 15 types of cancer. Dose-response relationships were modeled with restricted cubic spline functions that compared 7.5, 15.0, 22.5, and 30.0 MET hours/week to no leisure-time physical activity, and statistically significant associations were determined using tests for trend (P <.05) and 95% CIs (<1.0). RESULTS A total of 755,459 participants (median age, 62 years [range, 32-91 years]; 53% female) were followed for 10.1 years, and 50,620 incident cancers accrued. Engagement in recommended amounts of activity (7.5-15 MET hours/week) was associated with a statistically significant lower risk of 7 of the 15 cancer types studied, including colon (8%-14% lower risk in men), breast (6%-10% lower risk), endometrial (10%-18% lower risk), kidney (11%-17% lower risk), myeloma (14%-19% lower risk), liver (18%-27% lower risk), and non-Hodgkin lymphoma (11%-18% lower risk in women). The dose response was linear in shape for half of the associations and nonlinear for the others. Results for moderate- and vigorous-intensity leisure-time physical activity were mixed. Adjustment for body mass index eliminated the association with endometrial cancer but had limited effect on other cancer types. CONCLUSION Health care providers, fitness professionals, and public health practitioners should encourage adults to adopt and maintain physical activity at recommended levels to lower risks of multip
- Published
- 2020
27. Endobronchial ultrasound-guided transbronchial needle aspirate for diagnosis of anaplastic large cell lymphoma of unusual presentation: A case report
- Author
-
Liliana Fernández-Trujillo, Juan Carlos Bravo, Eliana I. Morales, Daniela Arias, Valeria Zúñiga-Restrepo, and Luz F. Sua
- Subjects
Pulmonary and Respiratory Medicine ,Spondylodiscitis ,medicine.medical_specialty ,Pleural effusion ,Case Report ,Anaplastic large cell lymphoma (ALCL) ,Malignancy ,Prednisone ,hemic and lymphatic diseases ,Biopsy ,medicine ,Anaplastic lymphoma kinase ,Anaplastic lymphoma kinase (ALK) ,Anaplastic large-cell lymphoma ,lcsh:RC705-779 ,EBUS-TBNA ,medicine.diagnostic_test ,Rapid on-side evaluation (ROSE) ,business.industry ,lcsh:Diseases of the respiratory system ,NonHodgkin lymphoma ,medicine.disease ,Lymphoma ,Radiology ,business ,medicine.drug - Abstract
Anaplastic large cell lymphoma (ALCL) is a rare type of non-Hodgkin lymphoma (NHL) originated from mature post thymic T cells. They represent 1–3% of NHL. Different subtypes have been described: Anaplastic lymphoma kinase (ALK)-negative ALCL, ALK-positive ALCL and breast implant-associated ALCL. ALK-positive ALCL affects mainly the young and has better prognosis. We present a case report of an adult woman with AKL-positive ALCL, diagnosed by endobronchial ultrasound-guided transbronchial needle aspirate (EBUS-TBNA).A 59-year-old women with no history of breast implants, was admitted for a four-month low back pain. Initially, the patient was treated for a spondyloarthropathy, but due to persistence of the symptoms, a lumbosacral MRI was performed, showing changes in morphology and signal intensity in the vertebral body of L3, along with edema and a paravertebral collection that affected the left psoas muscle, suggesting granulomatous spondylodiscitis. Chest CT-scan showed mild left pleural effusion, subcarinal and right hiliar adenomegalies. An EBUS-TBNA with ROSE (rapid on-site evaluation) was performed showing positive findings for malignancy, suggestive of hematolymphoid neoplasia. Pathology analysis showed an AKL-positive ALCL. Additionally, a biopsy of paravertebral tissue biopsy was obtained, which was consistent with the nodal sample. Chemotherapy was initiated with the CHOP protocol: cyclophosphamide, hydroxydaunorubicin, vincristine sulfate and prednisone.EBUS-TBNA is a minimally invasive and safe technique for obtaining mediastinal samples. Collaboration with a cytopathologist trained to perform ROSE improves the diagnostic performance. Keywords: Anaplastic large cell lymphoma (ALCL), Anaplastic lymphoma kinase (ALK), NonHodgkin lymphoma, EBUS-TBNA, Rapid on-side evaluation (ROSE)
- Published
- 2020
28. Exposure to permethrin and cancer risk: a systematic review
- Author
-
Paolo Boffetta, Vimi Desai, and Boffetta, P. and Desai, V.
- Subjects
Male ,permethrin ,Oncology ,Insecticides ,Review ,cancer risk ,010501 environmental sciences ,Toxicology ,01 natural sciences ,0302 clinical medicine ,Neoplasms ,Epidemiology ,permethrin, agriculture ,Multiple myeloma ,nonhodgkin lymphoma ,childhood leukemia ,leukemia ,Environmental exposure ,prostate cancer ,multiple myeloma ,Leukemia ,colon cancer ,rectum cancer ,030220 oncology & carcinogenesis ,bladder cancer ,Female ,epidemiology ,medicine.drug ,Risk ,medicine.medical_specialty ,Childhood leukemia ,03 medical and health sciences ,breast cancer ,pancreas cancer ,Internal medicine ,melanoma ,medicine ,Humans ,cancer ,human ,0105 earth and related environmental sciences ,business.industry ,disease association ,insecticide ,Cancer ,Environmental Exposure ,Odds ratio ,medicine.disease ,human tissue ,lung cancer ,Carcinogens ,business ,Permethrin - Abstract
No systematic reviews are available on data from humans on cancer risk from exposure to permethrin, a widely used insecticide for which some animal studies have reported positive findings based on mechanisms that may not be relevant to humans. We identified potentially relevant articles through a search of electronic databases which included all studies of pesticide exposure and human cancer. A total of 18 articles were selected, including six identified from the list of references of other articles. Most articles were based on analyzes of the Agriculture Health Study (AHS); they provided no evidence of an increased risk of cancers of colon, rectum, pancreas, lung, melanoma, female breast, prostate, urinary bladder, as well as non-Hodgkin lymphoma (including its main subtypes), and leukemia. An increased risk of multiple myeloma was reported among AHS members with the highest tertile of estimated permethrin exposure (odds ratio 5.01; 95% confidence interval 2.41–10.42; p for trend
- Published
- 2018
29. Cardiac and hepatic siderosis in myelodysplastic syndrome, thalassemia and diverse causes of transfusion-dependent anemia: The TIMES study.
- Abstract
The significant morbidity and mortality associated with iron overload can be reduced by effective iron chelation. Magnetic resonance imaging (MRI) provides accurate and reproducible iron load assessment. The aim of this epidemiological study was to assess the prevalence and severity of cardiac and hepatic siderosis by MRI and to evaluate the impact of MRI on clinical management in patients with transfusion-dependent anemia and non-transfusion-dependent thalassemia (NTDT). We enrolled 243 patients with myelodysplastic syndromes (MDS), thalassemia major (TM), NTDT or other chronic anemia. Overall, 10% and 48% had cardiac and hepatic siderosis, respectively. Mean liver iron concentration (LIC) was above target range in all groups; mean myocardial T2* was normal. Hepatic siderosis was more prevalent than myocardial siderosis in patients with MDS, occurring in 54.4% and 4.4% of patients, respectively. As also observed in patients with NTDT or other anemia, hepatic siderosis was present in a large proportion of MDS patients who were chelation naive (57.7%), as well as in patients receiving iron chelation therapy (ICT) (52.4%), despite a lower transfusion load compared with TM. Correlation between LIC and serum ferritin was observed across diseases; however, not all patients requiring ICT could be identified with serum ferritin alone, as serum ferritin underestimated LIC in 4.4% and overestimated LIC in 7.5% of patients. Exploratory analyses showed serum ferritin thresholds for liver siderosis detected by MRI at approximately 300 ng/mL higher in MDS than in TM. Most patients reported low-medium adherence to ICT; MRI assessment led to change in ICT in 46% of evaluable patients, including 52% of MDS patients. Accurate organ iron monitoring by MRI facilitated appropriate initiation of chelation, dose optimization and clinical decision making.Trial registration: ClinicalTrials.gov: NCT01736540.Copyright © 2019 the Author(s). Published by Wolters Kluwer Health, Inc.
- Published
- 2019
30. Mosunetuzumab Induces Complete Remissions in Poor Prognosis Non-Hodgkin Lymphoma Patients, Including Those Who Are Resistant to or Relapsing After Chimeric Antigen Receptor T-Cell (CAR-T) Therapies, and Is Active in Treatment through Multiple Lines.
- Abstract
DISCLOSURES: Schuster: Novartis: Honoraria, Patents & Royalties: Combination CAR-T and PD-1 Inhibitors, Research Funding; Nordic Nanovector: Consultancy, Honoraria; AstraZeneca: Consultancy, Honoraria; AbbVie: Consultancy, Honoraria, Research Funding; Pharmacyclics: Consultancy, Honoraria, Research Funding; Celgene: Consultancy, Honoraria, Research Funding; Acerta: Consultancy, Honoraria, Research Funding; Gilead: Consultancy, Honoraria, Research Funding; Loxo Oncology: Consultancy, Honoraria; Merck: Consultancy, Honoraria, Research Funding; Pfizer: Consultancy, Honoraria; Genentech: Consultancy, Honoraria, Research Funding. Bartlett:Bristol-Myers Squibb: Research Funding; Celgene: Research Funding; Kite Pharma: Research Funding; Merck: Research Funding; Millennium: Research Funding; Pfizer: Research Funding; Pharmacyclics: Research Funding; Gilead: Research Funding; Immune Design: Research Funding; Incyte: Research Funding; Janssen: Research Funding; ADC Therapeutics: Membership on an entity's Board of Directors or advisory committees, Research Funding; Affimed: Research Funding; Autolus: Research Funding; Forty Seven: Research Funding; Genentech, Inc.: Research Funding. Assouline:Janssen: Consultancy, Honoraria, Speakers Bureau; F. Hoffmann-La Roche Ltd: Consultancy, Honoraria; Abbvie: Consultancy, Honoraria; Pfizer: Consultancy, Honoraria, Speakers Bureau. Yoon:Kyowa Hako Kirin: Research Funding; Genentech, Inc.: Research Funding; Novartis: Consultancy, Honoraria; Amgen: Consultancy, Honoraria; MSD: Consultancy; Janssen: Consultancy; Yuhan Pharma: Research Funding. Bosch:Kyte: Consultancy, Honoraria, Membership on an entity's Board of Directors or advisory committees, Research Funding, Speakers Bureau; Acerta: Consultancy, Honoraria, Membership on an entity's Board of Directors or advisory committees, Research Funding, Speakers Bureau; Celgene: Honoraria, Research Funding; Janssen: Consultancy, Honoraria, Membership on an entity's Board of Directors or advisory c
- Published
- 2019
31. A phase 1/1b study to evaluate the humanized anti-CD73 antibody, CPI-006, as a single agent, in combination with CPI-444, and in combination with pembrolizumab in adult patients with advanced cancers.
- Abstract
Background CD73 expression is elevated in tumors and contributes to increasing levels of immunosuppressive adenosine in the tumor microenvironment. CD73 knockout mice exhibit reduced tumor growth and resistance to experimental metastasis. Inhibition of CD73 activity with an anti-CD73 antibody blocks adenosine production, shown to inhibit tumor growth in syngeneic models. Dual inhibition of CD73 and A2aR improves anti-tumor immune responses in mouse tumor models[1]. CPI-006 is a humanized IgG1 Fc gamma receptor binding-deficient anti-CD73 antibody that has a dual mechanism of action. It blocks CD73 catalytic activity and adenosine production. In addition, it has immunomodulatory activity on CD73 positive immune cells including B cells, T cells and antigen presenting cells. CPI-006 relieves adenosine-mediated immunosuppression in vitro as a single agent and in combination with ciforadenant[2]. CPI-006 is now being investigated in this Phase 1/1b multicenter, open label trial as single agent (SA), in combination with ciforadenant, an oral, small molecule, selective A2aR antagonist and in combination with pembrolizumab, an anti-PD1 indicated for the treatment of patients across a number of malignancies (NCT03454451). Methods Up to 462 subjects will be enrolled at approximately 35 sites in the US, Canada and Australia. Eligible patients with: non-small cell lung cancer (NSCLC), renal cell carcinoma cancer (RCC), urothelial bladder cancer, cervical cancer, colorectal cancer, ovarian cancer, pancreatic cancer, prostate cancer, head and neck cancer, triple-negative breast cancer, endometrial cancer, select sarcomas and non-Hodgkin lymphoma (NHL) who are relapsed, refractory or intolerant to 1 to 5 standard therapies; aged >= 18 yo; with adequate organ function and measurable disease. Study details is presented in Figure 1. The primary objective of the dose escalation is to assess safety/ tolerability, MTD or MDL of CPI-006 SA, in combination with ciforadenant and with pembr
- Published
- 2019
32. Cardiac and hepatic siderosis in myelodysplastic syndrome, thalassemia and diverse causes of transfusion-dependent anemia: The TIMES study.
- Abstract
The significant morbidity and mortality associated with iron overload can be reduced by effective iron chelation. Magnetic resonance imaging (MRI) provides accurate and reproducible iron load assessment. The aim of this epidemiological study was to assess the prevalence and severity of cardiac and hepatic siderosis by MRI and to evaluate the impact of MRI on clinical management in patients with transfusion-dependent anemia and non-transfusion-dependent thalassemia (NTDT). We enrolled 243 patients with myelodysplastic syndromes (MDS), thalassemia major (TM), NTDT or other chronic anemia. Overall, 10% and 48% had cardiac and hepatic siderosis, respectively. Mean liver iron concentration (LIC) was above target range in all groups; mean myocardial T2* was normal. Hepatic siderosis was more prevalent than myocardial siderosis in patients with MDS, occurring in 54.4% and 4.4% of patients, respectively. As also observed in patients with NTDT or other anemia, hepatic siderosis was present in a large proportion of MDS patients who were chelation naive (57.7%), as well as in patients receiving iron chelation therapy (ICT) (52.4%), despite a lower transfusion load compared with TM. Correlation between LIC and serum ferritin was observed across diseases; however, not all patients requiring ICT could be identified with serum ferritin alone, as serum ferritin underestimated LIC in 4.4% and overestimated LIC in 7.5% of patients. Exploratory analyses showed serum ferritin thresholds for liver siderosis detected by MRI at approximately 300 ng/mL higher in MDS than in TM. Most patients reported low-medium adherence to ICT; MRI assessment led to change in ICT in 46% of evaluable patients, including 52% of MDS patients. Accurate organ iron monitoring by MRI facilitated appropriate initiation of chelation, dose optimization and clinical decision making.Trial registration: ClinicalTrials.gov: NCT01736540.Copyright © 2019 the Author(s). Published by Wolters Kluwer Health, Inc.
- Published
- 2019
33. Mosunetuzumab Induces Complete Remissions in Poor Prognosis Non-Hodgkin Lymphoma Patients, Including Those Who Are Resistant to or Relapsing After Chimeric Antigen Receptor T-Cell (CAR-T) Therapies, and Is Active in Treatment through Multiple Lines.
- Abstract
DISCLOSURES: Schuster: Novartis: Honoraria, Patents & Royalties: Combination CAR-T and PD-1 Inhibitors, Research Funding; Nordic Nanovector: Consultancy, Honoraria; AstraZeneca: Consultancy, Honoraria; AbbVie: Consultancy, Honoraria, Research Funding; Pharmacyclics: Consultancy, Honoraria, Research Funding; Celgene: Consultancy, Honoraria, Research Funding; Acerta: Consultancy, Honoraria, Research Funding; Gilead: Consultancy, Honoraria, Research Funding; Loxo Oncology: Consultancy, Honoraria; Merck: Consultancy, Honoraria, Research Funding; Pfizer: Consultancy, Honoraria; Genentech: Consultancy, Honoraria, Research Funding. Bartlett:Bristol-Myers Squibb: Research Funding; Celgene: Research Funding; Kite Pharma: Research Funding; Merck: Research Funding; Millennium: Research Funding; Pfizer: Research Funding; Pharmacyclics: Research Funding; Gilead: Research Funding; Immune Design: Research Funding; Incyte: Research Funding; Janssen: Research Funding; ADC Therapeutics: Membership on an entity's Board of Directors or advisory committees, Research Funding; Affimed: Research Funding; Autolus: Research Funding; Forty Seven: Research Funding; Genentech, Inc.: Research Funding. Assouline:Janssen: Consultancy, Honoraria, Speakers Bureau; F. Hoffmann-La Roche Ltd: Consultancy, Honoraria; Abbvie: Consultancy, Honoraria; Pfizer: Consultancy, Honoraria, Speakers Bureau. Yoon:Kyowa Hako Kirin: Research Funding; Genentech, Inc.: Research Funding; Novartis: Consultancy, Honoraria; Amgen: Consultancy, Honoraria; MSD: Consultancy; Janssen: Consultancy; Yuhan Pharma: Research Funding. Bosch:Kyte: Consultancy, Honoraria, Membership on an entity's Board of Directors or advisory committees, Research Funding, Speakers Bureau; Acerta: Consultancy, Honoraria, Membership on an entity's Board of Directors or advisory committees, Research Funding, Speakers Bureau; Celgene: Honoraria, Research Funding; Janssen: Consultancy, Honoraria, Membership on an entity's Board of Directors or advisory c
- Published
- 2019
34. A phase 1/1b study to evaluate the humanized anti-CD73 antibody, CPI-006, as a single agent, in combination with CPI-444, and in combination with pembrolizumab in adult patients with advanced cancers.
- Abstract
Background CD73 expression is elevated in tumors and contributes to increasing levels of immunosuppressive adenosine in the tumor microenvironment. CD73 knockout mice exhibit reduced tumor growth and resistance to experimental metastasis. Inhibition of CD73 activity with an anti-CD73 antibody blocks adenosine production, shown to inhibit tumor growth in syngeneic models. Dual inhibition of CD73 and A2aR improves anti-tumor immune responses in mouse tumor models[1]. CPI-006 is a humanized IgG1 Fc gamma receptor binding-deficient anti-CD73 antibody that has a dual mechanism of action. It blocks CD73 catalytic activity and adenosine production. In addition, it has immunomodulatory activity on CD73 positive immune cells including B cells, T cells and antigen presenting cells. CPI-006 relieves adenosine-mediated immunosuppression in vitro as a single agent and in combination with ciforadenant[2]. CPI-006 is now being investigated in this Phase 1/1b multicenter, open label trial as single agent (SA), in combination with ciforadenant, an oral, small molecule, selective A2aR antagonist and in combination with pembrolizumab, an anti-PD1 indicated for the treatment of patients across a number of malignancies (NCT03454451). Methods Up to 462 subjects will be enrolled at approximately 35 sites in the US, Canada and Australia. Eligible patients with: non-small cell lung cancer (NSCLC), renal cell carcinoma cancer (RCC), urothelial bladder cancer, cervical cancer, colorectal cancer, ovarian cancer, pancreatic cancer, prostate cancer, head and neck cancer, triple-negative breast cancer, endometrial cancer, select sarcomas and non-Hodgkin lymphoma (NHL) who are relapsed, refractory or intolerant to 1 to 5 standard therapies; aged >= 18 yo; with adequate organ function and measurable disease. Study details is presented in Figure 1. The primary objective of the dose escalation is to assess safety/ tolerability, MTD or MDL of CPI-006 SA, in combination with ciforadenant and with pembr
- Published
- 2019
35. A case report of angioimmunoblastic T-cell lymphoma in a 16-year-old patient.
- Author
-
Ehsani, M. and Hosseini, A. R.
- Subjects
- *
CASE studies , *T-cell lymphoma , *HIV , *PATHOLOGISTS - Abstract
Background: Angioimmunoblastic T-cell lymphoma (AITL) which is recognized in the current world health organization classification as a peripheral T-cell lymphoma of the nonhodgkin lymphomas, comprises about 1% of all lymphomas. The average age at the time of diagnosis of AITL is about 65 years and it is rarely seen in patients under 18 years. Case report: A 16-year-old boy suffering from fever, weakness, paleness, and axillary lymphadenopathy was referred to Kashan Shahid Beheshti hospital. Laboratory tests showed pancytopenia and elevated LDH. Splenomegaly and normal liver size were also reported by sonographist. Bone marrow aspiration was normal and reactive follicular hyperplasia was reported on the first biopsy of axillary lymph node, but with continuing fever and pancytopenia biopsy of the axillary lymph node was performed again and this time AITL was also reported using the pathological and immunohistochemical evaluation. Conclusion: AITL, a rare lymphoma under 18 years old, typically manifested by lymphadenopathy, splenomegaly, elevated serum LDH and systemic B-symptoms. One of the most common differential diagnoses of AITL is reactive t-cell infiltrative processes which in some cases pathologists may have difficulty distinguishing between them. The diagnosis was confirmed by immunophenotyping and pathology of the axillary lymph nodes. [ABSTRACT FROM AUTHOR]
- Published
- 2012
36. Who is WHO and what was REAL?
- Author
-
Swiss Medical Weekly
- Subjects
Hodgkin lymphoma ,NonHodgkin lymphoma ,Kiel ,REAL ,WHO ,Lymphoma classification ,Medicine - Published
- 2002
- Full Text
- View/download PDF
37. Global, Regional, and National Cancer Incidence, Mortality, Years of Life Lost, Years Lived With Disability, and Disability-Adjusted Life-Years for 29 Cancer Groups, 1990 to 2017: A Systematic Analysis for the Global Burden of Disease Study
- Author
-
Global Burden of Disease Cancer Collaboration, Fitzmaurice C, Abate D, Abbasi N, Abbastabar H, Abd-Allah F, Abdel-Rahman O, Abdelalim A, Abdoli A, Abdollahpour I, Abdulle ASM, Abebe ND, Abraha HN, Abu-Raddad LJ, Abualhasan A, Adedeji IA, Advani SM, Afarideh M, Afshari M, Aghaali M, Agius D, Agrawal S, Ahmadi A, Ahmadian E, Ahmadpour E, Ahmed MB, Akbari ME, Akinyemiju T, Al-Aly Z, AlAbdulKader AM, Alahdab F, Alam T, Alamene GM, Alemnew BTT, Alene KA, Alinia C, Alipour V, Aljunid SM, Bakeshei FA, Almadi MAH, Almasi-Hashiani A, Alsharif U, Alsowaidi S, Alvis-Guzman N, Amini E, Amini S, Amoako YA, Anbari Z, Anber NH, Andrei CL, Anjomshoa M, Ansari F, Ansariadi A, Appiah SCY, Arab-Zozani M, Arabloo J, Arefi Z, Aremu O, Areri HA, Artaman A, Asayesh H, Asfaw ET, Ashagre AF, Assadi R, Ataeinia B, Atalay HT, Ataro Z, Atique S, Ausloos M, Avila-Burgos L, Avokpaho EFGA, Awasthi A, Awoke N, Ayala Quintanilla BP, Ayanore MA, Ayele HT, Babaee E, Bacha U, Badawi A, Bagherzadeh M, Bagli E, Balakrishnan S, Balouchi A, Bärnighausen TW, Battista RJ, Behzadifar M, Bekele BB, Belay YB, Belayneh YM, Berfield KKS, Berhane A, Bernabe E, Beuran M, Bhakta N, Bhattacharyya K, Biadgo B, Bijani A, Bin Sayeed MS, Birungi C, Bisignano C, Bitew H, Bjørge T, Bleyer A, Bogale KA, Bojia HA, Borzì AM, Bosetti C, Bou-Orm IR, Brenner H, Brewer JD, Briko AN, Briko NI, Bustamante-Teixeira MT, Butt ZA, Carreras G, Carrero JJ, Carvalho F, Castro C, Castro F, Catalá-López F, Cerin E, Chaiah Y, Chanie WF, Chattu VK, Chaturvedi P, Chauhan NS, Chehrazi M, Chiang PP, Chichiabellu TY, Chido-Amajuoyi OG, Chimed-Ochir O, Choi JJ, Christopher DJ, Chu DT, Constantin MM, Costa VM, Crocetti E, Crowe CS, Curado MP, Dahlawi SMA, Damiani G, Darwish AH, Daryani A, das Neves J, Demeke FM, Demis AB, Demissie BW, Demoz GT, Denova-Gutiérrez E, Derakhshani A, Deribe KS, Desai R, Desalegn BB, Desta M, Dey S, Dharmaratne SD, Dhimal M, Diaz D, Dinberu MTT, Djalalinia S, Doku DT, Drake TM, Dubey M, Dubljanin E, Duken EE, Ebrahimi H, Effiong A, Eftekhari A, El Sayed I, Zaki MES, El-Jaafary SI, El-Khatib Z, Elemineh DA, Elkout H, Ellenbogen RG, Elsharkawy A, Emamian MH, Endalew DA, Endries AY, Eshrati B, Fadhil I, Fallah V, Faramarzi M, Farhangi MA, Farioli A, Farzadfar F, Fentahun N, Fernandes E, Feyissa GT, Filip I, Fischer F, Fisher JL, Force LM, Foroutan M, Freitas M, Fukumoto T, Futran ND, Gallus S, Gankpe FG, Gayesa RT, Gebrehiwot TT, Gebremeskel GG, Gedefaw GA, Gelaw BK, Geta B, Getachew S, Gezae KE, Ghafourifard M, Ghajar A, Ghashghaee A, Gholamian A, Gill PS, Ginindza TTG, Girmay A, Gizaw M, Gomez RS, Gopalani SV, Gorini G, Goulart BNG, Grada A, Ribeiro Guerra M, Guimaraes ALS, Gupta PC, Gupta R, Hadkhale K, Haj-Mirzaian A, Hamadeh RR, Hamidi S, Hanfore LK, Haro JM, Hasankhani M, Hasanzadeh A, Hassen HY, Hay RJ, Hay SI, Henok A, Henry NJ, Herteliu C, Hidru HD, Hoang CL, Hole MK, Hoogar P, Horita N, Hosgood HD, Hosseini M, Hosseinzadeh M, Hostiuc M, Hostiuc S, Househ M, Hussen MM, Ileanu B, Ilic MD, Innos K, Irvani SSN, Iseh KR, Islam SMS, Islami F, Jafari Balalami N, Jafarinia M, Jahangiry L, Jahani MA, Jahanmehr N, Jakovljevic M, James SL, Javanbakht M, Jayaraman S, Jee SH, Jenabi E, Jha RP, Jonas JB, Jonnagaddala J, Joo T, Jungari SB, Jürisson M, Kabir A, Kamangar F, Karch A, Karimi N, Karimian A, Kasaeian A, Kasahun GG, Kassa B, Kassa TD, Kassaw MW, Kaul A, Keiyoro PN, Kelbore AG, Kerbo AA, Khader YS, Khalilarjmandi M, Khan EA, Khan G, Khang YH, Khatab K, Khater A, Khayamzadeh M, Khazaee-Pool M, Khazaei S, Khoja AT, Khosravi MH, Khubchandani J, Kianipour N, Kim D, Kim YJ, Kisa A, Kisa S, Kissimova-Skarbek K, Komaki H, Koyanagi A, Krohn KJ, Bicer BK, Kugbey N, Kumar V, Kuupiel D, La Vecchia C, Lad DP, Lake EA, Lakew AM, Lal DK, Lami FH, Lan Q, Lasrado S, Lauriola P, Lazarus JV, Leigh J, Leshargie CT, Liao Y, Limenih MA, Listl S, Lopez AD, Lopukhov PD, Lunevicius R, Madadin M, Magdeldin S, El Razek HMA, Majeed A, Maleki A, Malekzadeh R, Manafi A, Manafi N, Manamo WA, Mansourian M, Mansournia MA, Mantovani LG, Maroufizadeh S, Martini SMS, Mashamba-Thompson TP, Massenburg BB, Maswabi MT, Mathur MR, McAlinden C, McKee M, Meheretu HAA, Mehrotra R, Mehta V, Meier T, Melaku YA, Meles GG, Meles HG, Melese A, Melku M, Memiah PTN, Mendoza W, Menezes RG, Merat S, Meretoja TJ, Mestrovic T, Miazgowski B, Miazgowski T, Mihretie KMM, Miller TR, Mills EJ, Mir SM, Mirzaei H, Mirzaei HR, Mishra R, Moazen B, Mohammad DK, Mohammad KA, Mohammad Y, Darwesh AM, Mohammadbeigi A, Mohammadi H, Mohammadi M, Mohammadian M, Mohammadian-Hafshejani A, Mohammadoo-Khorasani M, Mohammadpourhodki R, Mohammed AS, Mohammed JA, Mohammed S, Mohebi F, Mokdad AH, Monasta L, Moodley Y, Moosazadeh M, Moossavi M, Moradi G, Moradi-Joo M, Moradi-Lakeh M, Moradpour F, Morawska L, Morgado-da-Costa J, Morisaki N, Morrison SD, Mosapour A, Mousavi SM, Muche AA, Muhammed OSS, Musa J, Nabhan AR, Naderi M, Nagarajan AJ, Nagel G, Nahvijou A, Naik G, Najafi F, Naldi L, Nam HS, Nasiri N, Nazari J, Negoi I, Neupane S, Newcomb PA, Nggada HA, Ngunjiri JW, Nguyen CT, Nikniaz L, Ningrum DNA, Nirayo YL, Nixon MR, Nnaji CA, Nojomi M, Nosratnejad S, Shiadeh MN, Obsa MS, Ofori-Asenso R, Ogbo FA, Oh IH, Olagunju AT, Olagunju TO, Oluwasanu MM, Omonisi AE, Onwujekwe OE, Oommen AM, Oren E, Ortega-Altamirano DDV, Ota E, Otstavnov SS, Owolabi MO, P A M, Padubidri JR, Pakhale S, Pakpour AH, Pana A, Park EK, Parsian H, Pashaei T, Patel S, Patil ST, Pennini A, Pereira DM, Piccinelli C, Pillay JD, Pirestani M, Pishgar F, Postma MJ, Pourjafar H, Pourmalek F, Pourshams A, Prakash S, Prasad N, Qorbani M, Rabiee M, Rabiee N, Radfar A, Rafiei A, Rahim F, Rahimi M, Rahman MA, Rajati F, Rana SM, Raoofi S, Rath GK, Rawaf DL, Rawaf S, Reiner RC, Renzaho AMN, Rezaei N, Rezapour A, Ribeiro AI, Ribeiro D, Ronfani L, Roro EM, Roshandel G, Rostami A, Saad RS, Sabbagh P, Sabour S, Saddik B, Safiri S, Sahebkar A, Salahshoor MR, Salehi F, Salem H, Salem MR, Salimzadeh H, Salomon JA, Samy AM, Sanabria J, Santric Milicevic MM, Sartorius B, Sarveazad A, Sathian B, Satpathy M, Savic M, Sawhney M, Sayyah M, Schneider IJC, Schöttker B, Sekerija M, Sepanlou SG, Sepehrimanesh M, Seyedmousavi S, Shaahmadi F, Shabaninejad H, Shahbaz M, Shaikh MA, Shamshirian A, Shamsizadeh M, Sharafi H, Sharafi Z, Sharif M, Sharifi A, Sharifi H, Sharma R, Sheikh A, Shirkoohi R, Shukla SR, Si S, Siabani S, Silva DAS, Silveira DGA, Singh A, Singh JA, Sisay S, Sitas F, Sobngwi E, Soofi M, Soriano JB, Stathopoulou V, Sufiyan MB, Tabarés-Seisdedos R, Tabuchi T, Takahashi K, Tamtaji OR, Tarawneh MR, Tassew SG, Taymoori P, Tehrani-Banihashemi A, Temsah MH, Temsah O, Tesfay BE, Tesfay FH, Teshale MY, Tessema GA, Thapa S, Tlaye KG, Topor-Madry R, Tovani-Palone MR, Traini E, Tran BX, Tran KB, Tsadik AG, Ullah I, Uthman OA, Vacante M, Vaezi M, Varona Pérez P, Veisani Y, Vidale S, Violante FS, Vlassov V, Vollset SE, Vos T, Vosoughi K, Vu GT, Vujcic IS, Wabinga H, Wachamo TM, Wagnew FS, Waheed Y, Weldegebreal F, Weldesamuel GT, Wijeratne T, Wondafrash DZ, Wonde TE, Wondmieneh AB, Workie HM, Yadav R, Yadegar A, Yadollahpour A, Yaseri M, Yazdi-Feyzabadi V, Yeshaneh A, Yimam MA, Yimer EM, Yisma E, Yonemoto N, Younis MZ, Yousefi B, Yousefifard M, Yu C, Zabeh E, Zadnik V, Moghadam TZ, Zaidi Z, Zamani M, Zandian H, Zangeneh A, Zaki L, Zendehdel K, Zenebe ZM, Zewale TA, Ziapour A, Zodpey S, Murray CJL, Fitzmaurice C., Abate D., Abbasi N., Abbastabar H., Abd-Allah F., Abdel-Rahman O., Abdelalim A., Abdoli A., Abdollahpour I., Abdulle A.S.M., Abebe N.D., Abraha H.N., Abu-Raddad L.J., Abualhasan A., Adedeji I.A., Advani S.M., Afarideh M., Afshari M., Aghaali M., Agius D., Agrawal S., Ahmadi A., Ahmadian E., Ahmadpour E., Ahmed M.B., Akbari M.E., Akinyemiju T., Al-Aly Z., Alabdulkader A.M., Alahdab F., Alam T., Alamene G.M., Alemnew B.T.T., Alene K.A., Alinia C., Alipour V., Aljunid S.M., Bakeshei F.A., Almadi M.A.H., Almasi-Hashiani A., Alsharif U., Alsowaidi S., Alvis-Guzman N., Amini E., Amini S., Amoako Y.A., Anbari Z., Anber N.H., Andrei C.L., Anjomshoa M., Ansari F., Ansariadi A., Appiah S.C.Y., Arab-Zozani M., Arabloo J., Arefi Z., Aremu O., Areri H.A., Artaman A., Asayesh H., Asfaw E.T., Ashagre A.F., Assadi R., Ataeinia B., Atalay H.T., Ataro Z., Atique S., Ausloos M., Avila-Burgos L., Avokpaho E.F.G.A., Awasthi A., Awoke N., Ayala Quintanilla B.P., Ayanore M.A., Ayele H.T., Babaee E., Bacha U., Badawi A., Bagherzadeh M., Bagli E., Balakrishnan S., Balouchi A., Barnighausen T.W., Battista R.J., Behzadifar M., Bekele B.B., Belay Y.B., Belayneh Y.M., Berfield K.K.S., Berhane A., Bernabe E., Beuran M., Bhakta N., Bhattacharyya K., Biadgo B., Bijani A., Bin Sayeed M.S., Birungi C., Bisignano C., Bitew H., Bjorge T., Bleyer A., Bogale K.A., Bojia H.A., Borzi A.M., Bosetti C., Bou-Orm I.R., Brenner H., Brewer J.D., Briko A.N., Briko N.I., Bustamante-Teixeira M.T., Butt Z.A., Carreras G., Carrero J.J., Carvalho F., Castro C., Castro F., Catala-Lopez F., Cerin E., Chaiah Y., Chanie W.F., Chattu V.K., Chaturvedi P., Chauhan N.S., Chehrazi M., Chiang P.P.-C., Chichiabellu T.Y., Chido-Amajuoyi O.G., Chimed-Ochir O., Choi J.-Y.J., Christopher D.J., Chu D.-T., Constantin M.-M., Costa V.M., Crocetti E., Crowe C.S., Curado M.P., Dahlawi S.M.A., Damiani G., Darwish A.H., Daryani A., Das Neves J., Demeke F.M., Demis A.B., Demissie B.W., Demoz G.T., Denova-Gutierrez E., Derakhshani A., Deribe K.S., Desai R., Desalegn B.B., Desta M., Dey S., Dharmaratne S.D., Dhimal M., Diaz D., Dinberu M.T.T., Djalalinia S., Doku D.T., Drake T.M., Dubey M., Dubljanin E., Duken E.E., Ebrahimi H., Effiong A., Eftekhari A., El Sayed I., Zaki M.E.S., El-Jaafary S.I., El-Khatib Z., Elemineh D.A., Elkout H., Ellenbogen R.G., Elsharkawy A., Emamian M.H., Endalew D.A., Endries A.Y., Eshrati B., Fadhil I., Fallah V., Faramarzi M., Farhangi M.A., Farioli A., Farzadfar F., Fentahun N., Fernandes E., Feyissa G.T., Filip I., Fischer F., Fisher J.L., Force L.M., Foroutan M., Freitas M., Fukumoto T., Futran N.D., Gallus S., Gankpe F.G., Gayesa R.T., Gebrehiwot T.T., Gebremeskel G.G., Gedefaw G.A., Gelaw B.K., Geta B., Getachew S., Gezae K.E., Ghafourifard M., Ghajar A., Ghashghaee A., Gholamian A., Gill P.S., Ginindza T.T.G., Girmay A., Gizaw M., Gomez R.S., Gopalani S.V., Gorini G., Goulart B.N.G., Grada A., Ribeiro Guerra M., Guimaraes A.L.S., Gupta P.C., Gupta R., Hadkhale K., Haj-Mirzaian A., Hamadeh R.R., Hamidi S., Hanfore L.K., Haro J.M., Hasankhani M., Hasanzadeh A., Hassen H.Y., Hay R.J., Hay S.I., Henok A., Henry N.J., Herteliu C., Hidru H.D., Hoang C.L., Hole M.K., Hoogar P., Horita N., Hosgood H.D., Hosseini M., Hosseinzadeh M., Hostiuc M., Hostiuc S., Househ M., Hussen M.M., Ileanu B., Ilic M.D., Innos K., Irvani S.S.N., Iseh K.R., Islam S.M.S., Islami F., Jafari Balalami N., Jafarinia M., Jahangiry L., Jahani M.A., Jahanmehr N., Jakovljevic M., James S.L., Javanbakht M., Jayaraman S., Jee S.H., Jenabi E., Jha R.P., Jonas J.B., Jonnagaddala J., Joo T., Jungari S.B., Jurisson M., Kabir A., Kamangar F., Karch A., Karimi N., Karimian A., Kasaeian A., Kasahun G.G., Kassa B., Kassa T.D., Kassaw M.W., Kaul A., Keiyoro P.N., Kelbore A.G., Kerbo A.A., Khader Y.S., Khalilarjmandi M., Khan E.A., Khan G., Khang Y.-H., Khatab K., Khater A., Khayamzadeh M., Khazaee-Pool M., Khazaei S., Khoja A.T., Khosravi M.H., Khubchandani J., Kianipour N., Kim D., Kim Y.J., Kisa A., Kisa S., Kissimova-Skarbek K., Komaki H., Koyanagi A., Krohn K.J., Bicer B.K., Kugbey N., Kumar V., Kuupiel D., La Vecchia C., Lad D.P., Lake E.A., Lakew A.M., Lal D.K., Lami F.H., Lan Q., Lasrado S., Lauriola P., Lazarus J.V., Leigh J., Leshargie C.T., Liao Y., Limenih M.A., Listl S., Lopez A.D., Lopukhov P.D., Lunevicius R., Madadin M., Magdeldin S., El Razek H.M.A., Majeed A., Maleki A., Malekzadeh R., Manafi A., Manafi N., Manamo W.A., Mansourian M., Mansournia M.A., Mantovani L.G., Maroufizadeh S., Martini S.M.S., Mashamba-Thompson T.P., Massenburg B.B., Maswabi M.T., Mathur M.R., McAlinden C., McKee M., Meheretu H.A.A., Mehrotra R., Mehta V., Meier T., Melaku Y.A., Meles G.G., Meles H.G., Melese A., Melku M., Memiah P.T.N., Mendoza W., Menezes R.G., Merat S., Meretoja T.J., Mestrovic T., Miazgowski B., Miazgowski T., Mihretie K.M.M., Miller T.R., Mills E.J., Mir S.M., Mirzaei H., Mirzaei H.R., Mishra R., Moazen B., Mohammad D.K., Mohammad K.A., Mohammad Y., Darwesh A.M., Mohammadbeigi A., Mohammadi H., Mohammadi M., Mohammadian M., Mohammadian-Hafshejani A., Mohammadoo-Khorasani M., Mohammadpourhodki R., Mohammed A.S., Mohammed J.A., Mohammed S., Mohebi F., Mokdad A.H., Monasta L., Moodley Y., Moosazadeh M., Moossavi M., Moradi G., Moradi-Joo M., Moradi-Lakeh M., Moradpour F., Morawska L., Morgado-Da-costa J., Morisaki N., Morrison S.D., Mosapour A., Mousavi S.M., Muche A.A., Muhammed O.S.S., Musa J., Nabhan A.R., Naderi M., Nagarajan A.J., Nagel G., Nahvijou A., Naik G., Najafi F., Naldi L., Nam H.S., Nasiri N., Nazari J., Negoi I., Neupane S., Newcomb P.A., Nggada H.A., Ngunjiri J.W., Nguyen C.T., Nikniaz L., Ningrum D.N.A., Nirayo Y.L., Nixon M.R., Nnaji C.A., Nojomi M., Nosratnejad S., Shiadeh M.N., Obsa M.S., Ofori-Asenso R., Ogbo F.A., Oh I.-H., Olagunju A.T., Olagunju T.O., Oluwasanu M.M., Omonisi A.E., Onwujekwe O.E., Oommen A.M., Oren E., Ortega-Altamirano D.D.V., Ota E., Otstavnov S.S., Owolabi M.O., P A M., Padubidri J.R., Pakhale S., Pakpour A.H., Pana A., Park E.-K., Parsian H., Pashaei T., Patel S., Patil S.T., Pennini A., Pereira D.M., Piccinelli C., Pillay J.D., Pirestani M., Pishgar F., Postma M.J., Pourjafar H., Pourmalek F., Pourshams A., Prakash S., Prasad N., Qorbani M., Rabiee M., Rabiee N., Radfar A., Rafiei A., Rahim F., Rahimi M., Rahman M.A., Rajati F., Rana S.M., Raoofi S., Rath G.K., Rawaf D.L., Rawaf S., Reiner R.C., Renzaho A.M.N., Rezaei N., Rezapour A., Ribeiro A.I., Ribeiro D., Ronfani L., Roro E.M., Roshandel G., Rostami A., Saad R.S., Sabbagh P., Sabour S., Saddik B., Safiri S., Sahebkar A., Salahshoor M.R., Salehi F., Salem H., Salem M.R., Salimzadeh H., Salomon J.A., Samy A.M., Sanabria J., Santric Milicevic M.M., Sartorius B., Sarveazad A., Sathian B., Satpathy M., Savic M., Sawhney M., Sayyah M., Schneider I.J.C., Schottker B., Sekerija M., Sepanlou S.G., Sepehrimanesh M., Seyedmousavi S., Shaahmadi F., Shabaninejad H., Shahbaz M., Shaikh M.A., Shamshirian A., Shamsizadeh M., Sharafi H., Sharafi Z., Sharif M., Sharifi A., Sharifi H., Sharma R., Sheikh A., Shirkoohi R., Shukla S.R., Si S., Siabani S., Silva D.A.S., Silveira D.G.A., Singh A., Singh J.A., Sisay S., Sitas F., Sobngwi E., Soofi M., Soriano J.B., Stathopoulou V., Sufiyan M.B., Tabares-Seisdedos R., Tabuchi T., Takahashi K., Tamtaji O.R., Tarawneh M.R., Tassew S.G., Taymoori P., Tehrani-Banihashemi A., Temsah M.-H., Temsah O., Tesfay B.E., Tesfay F.H., Teshale M.Y., Tessema G.A., Thapa S., Tlaye K.G., Topor-Madry R., Tovani-Palone M.R., Traini E., Tran B.X., Tran K.B., Tsadik A.G., Ullah I., Uthman O.A., Vacante M., Vaezi M., Varona Perez P., Veisani Y., Vidale S., Violante F.S., Vlassov V., Vollset S.E., Vos T., Vosoughi K., Vu G.T., Vujcic I.S., Wabinga H., Wachamo T.M., Wagnew F.S., Waheed Y., Weldegebreal F., Weldesamuel G.T., Wijeratne T., Wondafrash D.Z., Wonde T.E., Wondmieneh A.B., Workie H.M., Yadav R., Yadegar A., Yadollahpour A., Yaseri M., Yazdi-Feyzabadi V., Yeshaneh A., Yimam M.A., Yimer E.M., Yisma E., Yonemoto N., Younis M.Z., Yousefi B., Yousefifard M., Yu C., Zabeh E., Zadnik V., Moghadam T.Z., Zaidi Z., Zamani M., Zandian H., Zangeneh A., Zaki L., Zendehdel K., Zenebe Z.M., Zewale T.A., Ziapour A., Zodpey S., Murray C.J.L., Microbes in Health and Disease (MHD), Real World Studies in PharmacoEpidemiology, -Genetics, -Economics and -Therapy (PEGET), Value, Affordability and Sustainability (VALUE), Clinicum, Doctoral Programme in Clinical Research, HUS Comprehensive Cancer Center, Institute for Molecular Medicine Finland, Fitzmaurice, C, Abate, D, Abbasi, N, Abbastabar, H, Abd-Allah, F, Abdel-Rahman, O, Abdelalim, A, Abdoli, A, Abdollahpour, I, Abdulle, A, Abebe, N, Abraha, H, Abu-Raddad, L, Abualhasan, A, Adedeji, I, Advani, S, Afarideh, M, Afshari, M, Aghaali, M, Agius, D, Agrawal, S, Ahmadi, A, Ahmadian, E, Ahmadpour, E, Ahmed, M, Akbari, M, Akinyemiju, T, Al-Aly, Z, Alabdulkader, A, Alahdab, F, Alam, T, Alamene, G, Alemnew, B, Alene, K, Alinia, C, Alipour, V, Aljunid, S, Bakeshei, F, Almadi, M, Almasi-Hashiani, A, Alsharif, U, Alsowaidi, S, Alvis-Guzman, N, Amini, E, Amini, S, Amoako, Y, Anbari, Z, Anber, N, Andrei, C, Anjomshoa, M, Ansari, F, Ansariadi, A, Appiah, S, Arab-Zozani, M, Arabloo, J, Arefi, Z, Aremu, O, Areri, H, Artaman, A, Asayesh, H, Asfaw, E, Ashagre, A, Assadi, R, Ataeinia, B, Atalay, H, Ataro, Z, Atique, S, Ausloos, M, Avila-Burgos, L, Avokpaho, E, Awasthi, A, Awoke, N, Ayala Quintanilla, B, Ayanore, M, Ayele, H, Babaee, E, Bacha, U, Badawi, A, Bagherzadeh, M, Bagli, E, Balakrishnan, S, Balouchi, A, Barnighausen, T, Battista, R, Behzadifar, M, Bekele, B, Belay, Y, Belayneh, Y, Berfield, K, Berhane, A, Bernabe, E, Beuran, M, Bhakta, N, Bhattacharyya, K, Biadgo, B, Bijani, A, Bin Sayeed, M, Birungi, C, Bisignano, C, Bitew, H, Bjorge, T, Bleyer, A, Bogale, K, Bojia, H, Borzi, A, Bosetti, C, Bou-Orm, I, Brenner, H, Brewer, J, Briko, A, Briko, N, Bustamante-Teixeira, M, Butt, Z, Carreras, G, Carrero, J, Carvalho, F, Castro, C, Castro, F, Catala-Lopez, F, Cerin, E, Chaiah, Y, Chanie, W, Chattu, V, Chaturvedi, P, Chauhan, N, Chehrazi, M, Chiang, P, Chichiabellu, T, Chido-Amajuoyi, O, Chimed-Ochir, O, Choi, J, Christopher, D, Chu, D, Constantin, M, Costa, V, Crocetti, E, Crowe, C, Curado, M, Dahlawi, S, Damiani, G, Darwish, A, Daryani, A, Das Neves, J, Demeke, F, Demis, A, Demissie, B, Demoz, G, Denova-Gutierrez, E, Derakhshani, A, Deribe, K, Desai, R, Desalegn, B, Desta, M, Dey, S, Dharmaratne, S, Dhimal, M, Diaz, D, Dinberu, M, Djalalinia, S, Doku, D, Drake, T, Dubey, M, Dubljanin, E, Duken, E, Ebrahimi, H, Effiong, A, Eftekhari, A, El Sayed, I, Zaki, M, El-Jaafary, S, El-Khatib, Z, Elemineh, D, Elkout, H, Ellenbogen, R, Elsharkawy, A, Emamian, M, Endalew, D, Endries, A, Eshrati, B, Fadhil, I, Fallah, V, Faramarzi, M, Farhangi, M, Farioli, A, Farzadfar, F, Fentahun, N, Fernandes, E, Feyissa, G, Filip, I, Fischer, F, Fisher, J, Force, L, Foroutan, M, Freitas, M, Fukumoto, T, Futran, N, Gallus, S, Gankpe, F, Gayesa, R, Gebrehiwot, T, Gebremeskel, G, Gedefaw, G, Gelaw, B, Geta, B, Getachew, S, Gezae, K, Ghafourifard, M, Ghajar, A, Ghashghaee, A, Gholamian, A, Gill, P, Ginindza, T, Girmay, A, Gizaw, M, Gomez, R, Gopalani, S, Gorini, G, Goulart, B, Grada, A, Ribeiro Guerra, M, Guimaraes, A, Gupta, P, Gupta, R, Hadkhale, K, Haj-Mirzaian, A, Hamadeh, R, Hamidi, S, Hanfore, L, Haro, J, Hasankhani, M, Hasanzadeh, A, Hassen, H, Hay, R, Hay, S, Henok, A, Henry, N, Herteliu, C, Hidru, H, Hoang, C, Hole, M, Hoogar, P, Horita, N, Hosgood, H, Hosseini, M, Hosseinzadeh, M, Hostiuc, M, Hostiuc, S, Househ, M, Hussen, M, Ileanu, B, Ilic, M, Innos, K, Irvani, S, Iseh, K, Islam, S, Islami, F, Jafari Balalami, N, Jafarinia, M, Jahangiry, L, Jahani, M, Jahanmehr, N, Jakovljevic, M, James, S, Javanbakht, M, Jayaraman, S, Jee, S, Jenabi, E, Jha, R, Jonas, J, Jonnagaddala, J, Joo, T, Jungari, S, Jurisson, M, Kabir, A, Kamangar, F, Karch, A, Karimi, N, Karimian, A, Kasaeian, A, Kasahun, G, Kassa, B, Kassa, T, Kassaw, M, Kaul, A, Keiyoro, P, Kelbore, A, Kerbo, A, Khader, Y, Khalilarjmandi, M, Khan, E, Khan, G, Khang, Y, Khatab, K, Khater, A, Khayamzadeh, M, Khazaee-Pool, M, Khazaei, S, Khoja, A, Khosravi, M, Khubchandani, J, Kianipour, N, Kim, D, Kim, Y, Kisa, A, Kisa, S, Kissimova-Skarbek, K, Komaki, H, Koyanagi, A, Krohn, K, Bicer, B, Kugbey, N, Kumar, V, Kuupiel, D, La Vecchia, C, Lad, D, Lake, E, Lakew, A, Lal, D, Lami, F, Lan, Q, Lasrado, S, Lauriola, P, Lazarus, J, Leigh, J, Leshargie, C, Liao, Y, Limenih, M, Listl, S, Lopez, A, Lopukhov, P, Lunevicius, R, Madadin, M, Magdeldin, S, El Razek, H, Majeed, A, Maleki, A, Malekzadeh, R, Manafi, A, Manafi, N, Manamo, W, Mansourian, M, Mansournia, M, Mantovani, L, Maroufizadeh, S, Martini, S, Mashamba-Thompson, T, Massenburg, B, Maswabi, M, Mathur, M, Mcalinden, C, Mckee, M, Meheretu, H, Mehrotra, R, Mehta, V, Meier, T, Melaku, Y, Meles, G, Meles, H, Melese, A, Melku, M, Memiah, P, Mendoza, W, Menezes, R, Merat, S, Meretoja, T, Mestrovic, T, Miazgowski, B, Miazgowski, T, Mihretie, K, Miller, T, Mills, E, Mir, S, Mirzaei, H, Mishra, R, Moazen, B, Mohammad, D, Mohammad, K, Mohammad, Y, Darwesh, A, Mohammadbeigi, A, Mohammadi, H, Mohammadi, M, Mohammadian, M, Mohammadian-Hafshejani, A, Mohammadoo-Khorasani, M, Mohammadpourhodki, R, Mohammed, A, Mohammed, J, Mohammed, S, Mohebi, F, Mokdad, A, Monasta, L, Moodley, Y, Moosazadeh, M, Moossavi, M, Moradi, G, Moradi-Joo, M, Moradi-Lakeh, M, Moradpour, F, Morawska, L, Morgado-Da-costa, J, Morisaki, N, Morrison, S, Mosapour, A, Mousavi, S, Muche, A, Muhammed, O, Musa, J, Nabhan, A, Naderi, M, Nagarajan, A, Nagel, G, Nahvijou, A, Naik, G, Najafi, F, Naldi, L, Nam, H, Nasiri, N, Nazari, J, Negoi, I, Neupane, S, Newcomb, P, Nggada, H, Ngunjiri, J, Nguyen, C, Nikniaz, L, Ningrum, D, Nirayo, Y, Nixon, M, Nnaji, C, Nojomi, M, Nosratnejad, S, Shiadeh, M, Obsa, M, Ofori-Asenso, R, Ogbo, F, Oh, I, Olagunju, A, Olagunju, T, Oluwasanu, M, Omonisi, A, Onwujekwe, O, Oommen, A, Oren, E, Ortega-Altamirano, D, Ota, E, Otstavnov, S, Owolabi, M, P A, M, Padubidri, J, Pakhale, S, Pakpour, A, Pana, A, Park, E, Parsian, H, Pashaei, T, Patel, S, Patil, S, Pennini, A, Pereira, D, Piccinelli, C, Pillay, J, Pirestani, M, Pishgar, F, Postma, M, Pourjafar, H, Pourmalek, F, Pourshams, A, Prakash, S, Prasad, N, Qorbani, M, Rabiee, M, Rabiee, N, Radfar, A, Rafiei, A, Rahim, F, Rahimi, M, Rahman, M, Rajati, F, Rana, S, Raoofi, S, Rath, G, Rawaf, D, Rawaf, S, Reiner, R, Renzaho, A, Rezaei, N, Rezapour, A, Ribeiro, A, Ribeiro, D, Ronfani, L, Roro, E, Roshandel, G, Rostami, A, Saad, R, Sabbagh, P, Sabour, S, Saddik, B, Safiri, S, Sahebkar, A, Salahshoor, M, Salehi, F, Salem, H, Salem, M, Salimzadeh, H, Salomon, J, Samy, A, Sanabria, J, Santric Milicevic, M, Sartorius, B, Sarveazad, A, Sathian, B, Satpathy, M, Savic, M, Sawhney, M, Sayyah, M, Schneider, I, Schottker, B, Sekerija, M, Sepanlou, S, Sepehrimanesh, M, Seyedmousavi, S, Shaahmadi, F, Shabaninejad, H, Shahbaz, M, Shaikh, M, Shamshirian, A, Shamsizadeh, M, Sharafi, H, Sharafi, Z, Sharif, M, Sharifi, A, Sharifi, H, Sharma, R, Sheikh, A, Shirkoohi, R, Shukla, S, Si, S, Siabani, S, Silva, D, Silveira, D, Singh, A, Singh, J, Sisay, S, Sitas, F, Sobngwi, E, Soofi, M, Soriano, J, Stathopoulou, V, Sufiyan, M, Tabares-Seisdedos, R, Tabuchi, T, Takahashi, K, Tamtaji, O, Tarawneh, M, Tassew, S, Taymoori, P, Tehrani-Banihashemi, A, Temsah, M, Temsah, O, Tesfay, B, Tesfay, F, Teshale, M, Tessema, G, Thapa, S, Tlaye, K, Topor-Madry, R, Tovani-Palone, M, Traini, E, Tran, B, Tran, K, Tsadik, A, Ullah, I, Uthman, O, Vacante, M, Vaezi, M, Varona Perez, P, Veisani, Y, Vidale, S, Violante, F, Vlassov, V, Vollset, S, Vos, T, Vosoughi, K, Vu, G, Vujcic, I, Wabinga, H, Wachamo, T, Wagnew, F, Waheed, Y, Weldegebreal, F, Weldesamuel, G, Wijeratne, T, Wondafrash, D, Wonde, T, Wondmieneh, A, Workie, H, Yadav, R, Yadegar, A, Yadollahpour, A, Yaseri, M, Yazdi-Feyzabadi, V, Yeshaneh, A, Yimam, M, Yimer, E, Yisma, E, Yonemoto, N, Younis, M, Yousefi, B, Yousefifard, M, Yu, C, Zabeh, E, Zadnik, V, Moghadam, T, Zaidi, Z, Zamani, M, Zandian, H, Zangeneh, A, Zaki, L, Zendehdel, K, Zenebe, Z, Zewale, T, Ziapour, A, Zodpey, S, Murray, C, Fitzmaurice, Christina, Abate, Degu, Abbasi, Naghmeh, Abbastabar, Hedayat, Yisma, Engida, Murray, Christopher JL, and Global Burden of Disease Cancer Collaboration
- Subjects
Cancer Research ,age distribution ,cancer incidence ,Colorectal cancer ,GBD, DALY ,cancer risk ,Global Health ,Global Burden of Disease ,disease burden ,cause of death ,trachea cancer ,0302 clinical medicine ,systematic review ,Neoplasms ,quality adjusted life year ,11. Sustainability ,Epidemiology ,cancer mortality ,030212 general & internal medicine ,years of life lost ,Stomach cancer ,fertility ,disabled person ,stomach cancer ,disability-adjusted life year ,nonhodgkin lymphoma ,Incidence ,1. No poverty ,prostate cancer ,3. Good health ,income ,Oncology ,risk factor ,030220 oncology & carcinogenesis ,bladder cancer ,Quality-Adjusted Life Years ,medicine.medical_specialty ,sex difference ,3122 Cancers ,colorectal cancer ,bronchus cancer ,Article ,educational status ,Causes of cancer ,liver cancer ,03 medical and health sciences ,Breast cancer ,breast cancer ,Environmental health ,geographic distribution ,medicine ,Humans ,Disabled Persons ,human ,business.industry ,Correction ,Cancer ,non melanoma skin cancer ,medicine.disease ,years lived with disability ,lung cancer ,Years of potential life lost ,Skin cancer ,global disease burden ,business ,neoplasm ,RC ,uterine cervix cancer - Abstract
Importance: Cancer and other noncommunicable diseases (NCDs) are now widely recognized as a threat to global development. The latest United Nations high-level meeting on NCDs reaffirmed this observation and also highlighted the slow progress in meeting the 2011 Political Declaration on the Prevention and Control of Noncommunicable Diseases and the third Sustainable Development Goal. Lack of situational analyses, priority setting, and budgeting have been identified as major obstacles in achieving these goals. All of these have in common that they require information on the local cancer epidemiology. The Global Burden of Disease (GBD) study is uniquely poised to provide these crucial data. Objective: To describe cancer burden for 29 cancer groups in 195 countries from 1990 through 2017 to provide data needed for cancer control planning. Evidence Review: We used the GBD study estimation methods to describe cancer incidence, mortality, years lived with disability, years of life lost, and disability-Adjusted life-years (DALYs). Results are presented at the national level as well as by Socio-demographic Index (SDI), a composite indicator of income, educational attainment, and total fertility rate. We also analyzed the influence of the epidemiological vs the demographic transition on cancer incidence. Findings: In 2017, there were 24.5 million incident cancer cases worldwide (16.8 million without nonmelanoma skin cancer [NMSC]) and 9.6 million cancer deaths. The majority of cancer DALYs came from years of life lost (97%), and only 3% came from years lived with disability. The odds of developing cancer were the lowest in the low SDI quintile (1 in 7) and the highest in the high SDI quintile (1 in 2) for both sexes. In 2017, the most common incident cancers in men were NMSC (4.3 million incident cases); tracheal, bronchus, and lung (TBL) cancer (1.5 million incident cases); and prostate cancer (1.3 million incident cases). The most common causes of cancer deaths and DALYs for men were TBL cancer (1.3 million deaths and 28.4 million DALYs), liver cancer (572000 deaths and 15.2 million DALYs), and stomach cancer (542000 deaths and 12.2 million DALYs). For women in 2017, the most common incident cancers were NMSC (3.3 million incident cases), breast cancer (1.9 million incident cases), and colorectal cancer (819000 incident cases). The leading causes of cancer deaths and DALYs for women were breast cancer (601000 deaths and 17.4 million DALYs), TBL cancer (596000 deaths and 12.6 million DALYs), and colorectal cancer (414000 deaths and 8.3 million DALYs). Conclusions and Relevance: The national epidemiological profiles of cancer burden in the GBD study show large heterogeneities, which are a reflection of different exposures to risk factors, economic settings, lifestyles, and access to care and screening. The GBD study can be used by policy makers and other stakeholders to develop and improve national and local cancer control in order to achieve the global targets and improve equity in cancer care. © 2019 American Medical Association. All rights reserved.
- Published
- 2019
38. The evaluation of malignancies in Turkish primary immunodeficiency patients; a multicenter study
- Author
-
Ayca Kiykim, Şükrü Çekiç, Ahmet Ozen, Guzide Aksu, Sara Sebnem Kilic, Ayse Metin, Torehan Aslan, Caner Aytekin, Neslihan Edeer Karaca, Necil Kutukculer, Betül Sevinir, Yasin Karali, Elif Karakoç Aydıner, Safa Baris, Ege Üniversitesi, Bursa Uludağ Üniversitesi/Tıp Fakültesi/Çocuk Sağlığı ve Hastalıkları., Çekiç, Şükrü, Karalı, Yasin, Aslan, Törehan, Sevinir, Betül, Kılıç, Sara Şebnem, FFS-1974-2022, and AAH-1570-2021
- Subjects
Male ,Secondary ,Hematologic malignancy ,Turkey ,medicine.medical_treatment ,Lymphadenopathy ,Diseases ,Real time polymerase chain reaction ,Pediatrics ,Gene ,0302 clinical medicine ,Squamous cell carcinoma ,Guanine Nucleotide Exchange Factors ,Colon adenocarcinoma ,Neurilemoma ,Child ,Nephroblastoma ,Burkitt lymphoma ,Rectum carcinoma ,Prognosis ,Multicenter study ,Clinical trial ,Antineoplastic agent ,Child, Preschool ,Cohort ,Nonhodgkin lymphoma ,Cancer chemotherapy ,Cohort analysis ,Human ,medicine.medical_specialty ,Remission ,Immunology ,Major clinical study ,Article ,03 medical and health sciences ,Age ,Humoral immune deficiency ,Humans ,Acute myeloid leukemia ,Immunologic Deficiency Syndromes ,Infant ,Sex difference ,medicine.disease ,Mortality rate ,B cell lymphoma ,Lymphoma ,DOCK8 protein ,Malignant neoplasm ,030228 respiratory system ,DOCK8 Deficiency ,Cancer incidence ,Ataxia Telangiectasia ,Mutation ,ATM Protein ,Guanine nucleotide exchange factor ,Small cell sarcoma ,Allergy ,DOCK8 deficiency ,Immune deficiency ,Hematopoietic stem cell transplantation ,Turkey (republic) ,ataxia-telangiectasia ,T cell lymphoma ,Turkey (bird) ,Neoplasms ,Immunology and Allergy ,030212 general & internal medicine ,Thyroid papillary carcinoma ,Priority journal ,non-Hodgkin lymphoma ,Middle Aged ,Consanguineous marriage ,Cancer radiotherapy ,Bloom syndrome ,Female ,Hemangiopericytoma ,Adult ,Hodgkin disease ,Adolescent ,Primary Immunodeficiency Diseases ,Family history ,Wiskott Aldrich syndrome ,lymphoma ,primary immunodeficiency ,Malignancy ,Pathophysiology ,Common variable immunodeficiency ,Young Adult ,Internal medicine ,medicine ,cancer ,Hepatosplenomegaly ,Chemotherapy ,business.industry ,Cancer ,Combined immunodeficiency ,Solid malignant neoplasm ,Clinical feature ,Preschool child ,Pediatrics, Perinatology and Child Health ,Primary immunodeficiency ,Neoplasm ,business ,malignancy - Abstract
Background There are no data regarding the prevalence of malignancies in patients with primary immunodeficiency (PID) in Turkey. Along with the prevalence of malignancy, we aimed to present the types of malignancy and define the underlying immune deficiency of the patients. Method Between the years 1992 and 2018, from five tertiary immunology clinics, fifty-nine patients with PID who developed malignancy were included. All patients were evaluated for demographics, clinical features, and prognosis. Results The prevalence of malignancy in our cohort was detected as 0.9% (59/6392). The male-to-female ratio was 1.8 (38/21), and the median age of patients was 14 years (range: 1.5-51). The median age at diagnosis of malignancy was 10 years (range: 1.5-51). Ataxia-telangiectasia was the most frequent PID in patients with malignancy (n = 19, 32.2%), and non-Hodgkin lymphoma was the most common malignancy (n = 32, 51.6%). The rate of malignancy in DOCK8 deficiency (n = 7/43, 16.3%) was higher than AT (n = 19/193, 9.8%), Wiskott-Aldrich syndrome (n = 2/22, 9.1%), and common variable immunodeficiency (n = 11/205, 5.4%). EBV quantitative PCR was positive in 16 out of 53 patients (30.2%). Three patients had secondary malignancies. Remission was achieved in 26 patients (44.1%). However, 31 patients (52.5%) died. Two patients (3.4%) are still on chemotherapy. Conclusion This study is the largest cohort investigating the association of malignancy in patients with PID in Turkey. While lymphoid malignancies were the most common malignancy and observed more frequently in AT patients, the risk for malignancy was higher in patients with DOCK8 deficiency compared to AT.
- Published
- 2019
39. The effect of malnutrition on mortality in hospitalized patients with hematologic malignancy
- Author
-
Güray Saydam, Merve Yilmaz, Fahri Şahin, Fatoş Dilan Atilla, and Ege Üniversitesi
- Subjects
Male ,Hematologic malignancy ,hematologic disease ,chronic leukemia ,mortality rate ,high risk patient ,0302 clinical medicine ,cancer mortality ,Body Size ,acute leukemia ,030212 general & internal medicine ,C reactive protein ,nonhodgkin lymphoma ,biology ,Hand Strength ,GLIM criteria ,adult ,Mortality rate ,risk assessment ,Middle Aged ,multiple myeloma ,hospital patient ,Leukemia ,C-Reactive Protein ,nutritional assessment ,priority journal ,Oncology ,030220 oncology & carcinogenesis ,Hematologic Neoplasms ,Female ,patient ,medicine.medical_specialty ,Hodgkin disease ,Patients ,GLIM ,Nutritional Status ,Article ,03 medical and health sciences ,Internal medicine ,medicine ,Humans ,human ,Mortality ,albumin ,Aged ,body composition ,hand grip ,business.industry ,C-reactive protein ,Malnutrition ,Albumin ,Proteins ,medicine.disease ,major clinical study ,Lymphoma ,age ,physiology ,biology.protein ,mortality risk ,pathology ,protein ,business ,arm circumference - Abstract
Objectives: The aim of this study was to assess the association between malnutrition status with the (Global Leadership Initiative on Malnutrition) GLIM criteria and 1-year mortality in hospitalized patients with hematologic malignancy. Methods: This study included 120 hospitalized patients with hematologic malignancy. Patients who were at risk of malnutrition with NRS2002 were reevaluated with the GLIM criteria for defined malnutrition. Also, the mid-upper arm circumference (MUAC), calf circumference (CC), and handgrip (HG) were measured, and albumin, C reactive protein (CRP), and total protein were recorded to assess malnutrition-related factors. Results: A total of 120 patients are with lymphoma, leukemia, and myeloma having a rate of 34.2%, 34.2%, and 31.6%, respectively, and risk of malnutrition with NRS2002 was established in 82% of patients. Malnutrition with GLIM criteria was seen in 25.8% of patients. The 1-year mortality rate was 41.7% (n = 50). Malnutrition was associated with higher mortality risk independently with age and duration of diagnosis (HR 3.55 (1.99–6.34), p = 0.001). Low HG (HR 0.51 (0.26–0.99), p = 0.03), low albumin (HR 0.39 (0.2–0.6), p = 0.001), and high CRP (HR 2.39 (1.36–4.20), p = 0.002) were significantly associated with increased mortality risk. In contrast, BMI, MUAC, FFMI, and CC were not associated with higher mortality. Conclusion: Malnutrition is high with the GLIM criteria. Hospitalized patients with hematologic malignancy with malnutrition have a higher 1-year mortality risk. © 2019, Springer-Verlag GmbH Germany, part of Springer Nature., The authors would like to thank the members of the Ege University Hospital Department of Internal Medicine, Division of Hematology (Nur Soyer, Filiz Vural, Mahmut Tobu, Murat Tombuloglu, Ayhan Donmez).
- Published
- 2019
40. In vitro chemosensitivities of human tumor stem cells to the Phase II drug 4'-(9-acridinylamino)methanesulfon-m-anisidide and prospective in vivo correlations.
- Author
-
Ahmann, F R, Meyskens, F L, Jr, Moon, T E, Durie, B G, and Salmon, S E
- Subjects
Aminoacridines: toxicity ,Amsacrine ,Antineoplastic Agents: toxicity ,Cells ,Cultured ,Drug Evaluation ,Female ,Genital Neoplasms ,Female: drug therapy ,Hematopoietic Stem Cells: drug effects ,Hodgkin Disease: drug therapy ,Humans ,Leukemia: drug therapy ,Lung Neoplasms: drug therapy ,Melanoma: drug therapy ,Neoplasms: drug therapy ,Neuroblastoma: drug therapy ,Sarcoma: drug therapy ,Uterine Cervical Neoplasms: drug therapy ,amsacrine ,blood and hemopoietic system ,bone marrow cell ,cancer cell culture ,cancer chemotherapy ,child ,colony formation ,drug sensitivity ,female genital system ,human ,human cell ,leukemia ,nervous system ,neuroblastoma ,nonhodgkin lymphoma ,therapy ,uterine cervix cancer ,Aminoacridines ,Amsacrine ,Antineoplastic Agents ,Cells ,Cultured ,Drug Evaluation ,Female ,Genital Neoplasms ,Female ,Hematopoietic Stem Cells ,Hodgkin Disease ,Humans ,Leukemia ,Lung Neoplasms ,Melanoma ,Neoplasms ,Neuroblastoma ,Sarcoma ,Uterine Cervical Neoplasms - Abstract
A potential application of the human tumor stem cell colony assay is to guide Phase II clinical investigations by identifying classes of tumors (or individual patients) which are sensitive in vitro to a new antitumor compound. We have tested human tumor stem cells from 140 tumor biopsies representing 20 different tumor types for chemosensitivity to the Phase II drug 4'-(9-acridinylamino)methanesulfon-m-anisidide. In vitro sensitivity was defined as a reduction in the number of tumor colony-forming cells to 30% of the control or less after a 1-hr exposure to one-tenth of the pharmacologically achievable plasma concentration of 4'-(9-acridinylamino)methanesulfon-m-anisidide. In vitro sensitivity was found in 29 cases: non-Hodgkin's lymphoma (2 of 2); cervical carcinoma (1 of 1); sarcoma (3 of 6); neuroblastoma (1 of 2); acute myelogenous leukemia (6 of 16); chronic myelogenous leukemia (1 of 3); melanoma (8 of 34); uterine carcinoma (1 of 5); lung carcinoma (1 of 9); ovarian carcinoma (4 of 36); and breast carcinoma (1 of 11). Prospective in vitro-in vivo correlations in eight patients with various tumor types showed that three of three patients sensitive in vitro to 4'-(9-acridinylamino)methanesulfon-m-anisidide responded in vivo, while five of five patients resistant in vitro had no clinical response. The results provide support for further evaluation of the utility of the human tumor stem cell colony assay for targeting Phase II clinical trials.
- Published
- 1982
41. Safety and activity of the highly specific BTK inhibitor bgb-3111 in patients with indolent and aggressive non hodgkin's lymphoma.
- Abstract
Introduction Bruton's Tyrosine Kinase (BTK) plays a critical role in B-cell receptor (BCR) signaling, which mediates B-cell proliferation, migration, and adhesion (Rickert, 2013; Aalipour, 2013; Choe, 2016). The BCR pathway is an established therapeutic target in multiple subtypes of non-Hodgkin's lymphoma (NHL). BGB-3111 is a potent, highly specific, and irreversible BTK inhibitor, with greater selectivity for BTK vs other TEC- and EGFR-family kinases and demonstrates favorable pharmacokinetic and pharmacodynamic properties. We have previously shown complete and sustained BTK occupancy in both peripheral blood mononuclear cells (PBMCs) and lymph nodes (LN) in patients (pts) treated at the 160 mg BID dose in a phase 1 trial (Tam et al. ASH 2016). A recent update of clinical data suggests that complete and sustained BTK occupancy is associated with durable responses in pts with CLL/SLL and Waldenstrom's macroglobulinemia (Seymour et al. ICML 2017; Trotman et al. ICML 2017). Here, we present early safety and efficacy data in pts with other NHL subtypes: relapsed/refractory (R/R) diffuse large B-cell lymphoma (DLBCL), follicular lymphoma (FL), mantle cell lymphoma (MCL), and marginal zone lymphoma (MZL). Methods This is an open-label, multicenter, phase 1b study of BGB-3111 in pts with B-cell malignancies. Dose escalation included pts with R/R B-cell malignancies, while the expansion phase enrolled disease-specific cohorts at the recommended phase 2 dose (320 mg/d, given once daily [QD] or split as 160 mg twice-daily [BID]). Response was assessed per ICML criteria (Cheson 2014). Results As of 18 May 2017, 75 pts with NHL were enrolled, including 23 DLBCL, 31 MCL, 14 FL, and 7 MZL pts. Patient characteristics are shown in the Table. With the exception of 1 pt with treatment-naive MCL, all pts had R/R disease. Safety: Median follow - up was 7 months (range, 0.3-31.9). The most frequent adverse events (AEs) of any cause were contusion (22.7%), upper respiratory tract infe
- Published
- 2018
42. Safety and activity of the highly specific BTK inhibitor bgb-3111 in patients with indolent and aggressive non hodgkin's lymphoma.
- Abstract
Introduction Bruton's Tyrosine Kinase (BTK) plays a critical role in B-cell receptor (BCR) signaling, which mediates B-cell proliferation, migration, and adhesion (Rickert, 2013; Aalipour, 2013; Choe, 2016). The BCR pathway is an established therapeutic target in multiple subtypes of non-Hodgkin's lymphoma (NHL). BGB-3111 is a potent, highly specific, and irreversible BTK inhibitor, with greater selectivity for BTK vs other TEC- and EGFR-family kinases and demonstrates favorable pharmacokinetic and pharmacodynamic properties. We have previously shown complete and sustained BTK occupancy in both peripheral blood mononuclear cells (PBMCs) and lymph nodes (LN) in patients (pts) treated at the 160 mg BID dose in a phase 1 trial (Tam et al. ASH 2016). A recent update of clinical data suggests that complete and sustained BTK occupancy is associated with durable responses in pts with CLL/SLL and Waldenstrom's macroglobulinemia (Seymour et al. ICML 2017; Trotman et al. ICML 2017). Here, we present early safety and efficacy data in pts with other NHL subtypes: relapsed/refractory (R/R) diffuse large B-cell lymphoma (DLBCL), follicular lymphoma (FL), mantle cell lymphoma (MCL), and marginal zone lymphoma (MZL). Methods This is an open-label, multicenter, phase 1b study of BGB-3111 in pts with B-cell malignancies. Dose escalation included pts with R/R B-cell malignancies, while the expansion phase enrolled disease-specific cohorts at the recommended phase 2 dose (320 mg/d, given once daily [QD] or split as 160 mg twice-daily [BID]). Response was assessed per ICML criteria (Cheson 2014). Results As of 18 May 2017, 75 pts with NHL were enrolled, including 23 DLBCL, 31 MCL, 14 FL, and 7 MZL pts. Patient characteristics are shown in the Table. With the exception of 1 pt with treatment-naive MCL, all pts had R/R disease. Safety: Median follow - up was 7 months (range, 0.3-31.9). The most frequent adverse events (AEs) of any cause were contusion (22.7%), upper respiratory tract infe
- Published
- 2018
43. Disparities by race, age, and sex in the improvement of survival for lymphoma: Findings from a population-based study
- Author
-
Chi T. D. Tran, Hung N. Luu, Linh Cu Le, Paolo Boffetta, Xiao-Ou Shu, Wei Zheng, Thuan V. Tran, Jong Y. Park, Bashir Dabo, Madison Whitney, Harvey A. Risch, Fahad Mukhtar, Huong Tran, and Mukhtar, F. and Boffetta, P. and Dabo, B. and Park, J.Y. and Tran, C.T.D. and Tran, T.V. and Tran, H.T.-T. and Whitney, M. and Risch, H.A. and Le, L.C. and Zheng, W. and Shu, X.-O. and Luu, H.N.
- Subjects
0301 basic medicine ,Male ,cancer incidence ,very elderly ,Cancer Treatment ,lcsh:Medicine ,Sex Factor ,Hematologic Cancers and Related Disorders ,0302 clinical medicine ,hemic and lymphatic diseases ,Epidemiology of cancer ,Epidemiology ,cancer mortality ,middle aged ,Medicine and Health Sciences ,Ethnicities ,Age Factor ,lcsh:Science ,African American people ,cancer survival ,Non-Hodgkin lymphoma ,Multidisciplinary ,nonhodgkin lymphoma ,adult ,Hazard ratio ,Age Factors ,Hematology ,aged ,female ,Oncology ,030220 oncology & carcinogenesis ,Lymphomas ,survival analysis, Adult ,Research Article ,cancer epidemiology ,medicine.medical_specialty ,Population Group ,ethnic difference ,Hodgkin disease ,sex difference ,Article ,03 medical and health sciences ,Sex Factors ,Population Groups ,Diagnostic Medicine ,Internal medicine ,medicine ,Cancer Detection and Diagnosis ,Humans ,cancer registry ,human ,Survival analysis ,business.industry ,Hodgkin Lymphoma ,lcsh:R ,Cancer ,Cancers and Neoplasms ,medicine.disease ,major clinical study ,Survival Analysis ,Confidence interval ,Lymphoma ,Cancer registry ,030104 developmental biology ,age ,Age Groups ,Geriatrics ,People and Places ,lcsh:Q ,Population Groupings ,business ,population research - Abstract
Objective To evaluate improvement in survival of lymphoma patients from 1990 to 2014, stratified by age, sex and race using Surveillance Epidemiology and End-Result Survey Program (SEER) data. Study design and setting We identified 113,788 incident lymphoma cases from nine SEER cancer registries were followed up for cause-specific mortality from lymphoma. Cox proportional hazard regression was used to estimate hazard ratios (HRs) and their respective 95% confidence interval (CIs) for various time periods within groups stratified by race, age and sex. Results Five-year survival for Hodgkin’s lymphoma (HL) was 89% for patients 20–49 years of age. For this age group, compared to 1990–1994, survival significantly improved in 2000–2004 (HR = 0.65; 95% CI: 0.54–0.78), 2005–2009 (HR = 0.46, 95% CI: 0.38–0.57) and 2010–2014 (HR = 0.29, 95% CI: 0.20–0.41). Hodgkin’s lymphoma patients aged 75–85 years had 5-year survival of 37% and in these patients, compared to 1990-1994, survival only improved from 2005 onward (HR = 0.67, 95% CI: 0.50–0.90). In patients with non-Hodgkin’s Lymphoma (NHL), all age groups showed survival improvements between 1990–1994 period and 2010–2014 period. Improvements in HL and NHL survival were seen for all race categories and both genders. Conclusion Survival among US lymphoma patients has improved substantially between 1990–1994 period and 2010–2014 period, though disease-specific mortality was still higher in older age groups. © 2018 Mukhtar et al. This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
- Published
- 2018
44. Opportunistic infections and AIDS malignancies early after initiating combination antiretroviral therapy in high-income countries
- Subjects
cryptococcosis ,opportunistic infection ,Herpes simplex virus ,acquired immune deficiency syndrome ,progressive multifocal leukoencephalopathy ,male ,virus infection ,Immune reconstitution inflammatory syndrome ,follow up ,human ,Inverse probability weighting ,outcome assessment ,nonhodgkin lymphoma ,antiretrovirus agent ,Cytomegalovirus retinitis ,Incidence ,adult ,article ,HIV ,CD4 lymphocyte count ,Kaposi sarcoma ,highly active antiretroviral therapy ,candidiasis ,immune reconstitution inflammatory syndrome ,major clinical study ,female ,tuberculosis ,Unmasking ,incidence - Abstract
Background: There is little information on the incidence of AIDS-defining events which have been reported in the literature to be associated with immune reconstitution inflammatory syndrome (IRIS) after combined antiretroviral therapy (cART) initiation. These events include tuberculosis, mycobacterium avium complex (MAC), cytomegalovirus (CMV) retinitis, progressive multifocal leukoencephalopathy (PML), herpes simplex virus (HSV), Kaposi sarcoma, non-Hodgkin lymphoma (NHL), cryptococcosis and candidiasis.Methods: We identified individuals in the HIV-CAUSAL Collaboration, which includes data from six European countries and the US, who were HIV-positive between 1996 and 2013, antiretroviral therapy naive, aged at least 18 years, hadCD4+cell count and HIV-RNA measurements and had been AIDS-free for at least 1 month between those measurements and the start of follow-up. For each AIDS-defining event, we estimated the hazard ratio for no cART versus less than 3 and at least 3 months since cART initiation, adjusting for time-varying CD4+cell count and HIV-RNA via inverse probability weighting.Results: Out of 96 562 eligible individuals (78% men) with median (interquantile range) follow-up of 31 [13,65] months, 55 144 initiated cART. The number of cases varied between 898 for tuberculosis and 113 for PML. Compared with non-cART initiation, the hazard ratio (95% confidence intervals) up to 3 months after cART initiation were 1.21 (0.90-1.63) for tuberculosis, 2.61 (1.05-6.49) for MAC, 1.17 (0.34-4.08) for CMV retinitis, 1.18 (0.62-2.26) for PML, 1.21 (0.83-1.75) for HSV, 1.18 (0.87-1.58) for Kaposi sarcoma, 1.56 (0.82-2.95) for NHL, 1.11 (0.56-2.18) for cryptococcosis and 0.77 (0.40-1.49) for candidiasis.Conclusion: With the potential exception of mycobacterial infections, unmasking IRIS does not appear to be a common complication of cART initiation in high-income countries.
- Published
- 2014
45. Other cancers in lung cancer families are overwhelmingly smoking-related cancers
- Author
-
Hongyao Yu, Akseli Hemminki, Christoph Frank, Kristina Sundquist, Kari Hemminki, Department of Oncology, Faculty of Medicine, University of Helsinki, Clinicum, HUS Comprehensive Cancer Center, and University of Helsinki, Department of Oncology
- Subjects
0301 basic medicine ,Oncology ,cancer patient ,lcsh:Medicine ,cancer risk ,cancer family ,0302 clinical medicine ,cancer diagnosis ,Epidemiology of cancer ,carcinogenicity ,child ,nonhodgkin lymphoma ,adult ,respiratory system ,3. Good health ,aged ,female ,medicine.anatomical_structure ,esophagus cancer ,030220 oncology & carcinogenesis ,Pulmonary and Respiratory Medicine ,medicine.medical_specialty ,3122 Cancers ,Article ,smoking ,03 medical and health sciences ,male ,Internal medicine ,medicine ,cancer registry ,Cancer Family ,human ,Risk factor ,Lung cancer ,Lung ,business.industry ,lcsh:R ,Cancer ,Original Articles ,lung adenocarcinoma ,medicine.disease ,cancer classification ,major clinical study ,Cancer registry ,respiratory tract diseases ,lung cancer ,030104 developmental biology ,adolescent ,Relative risk ,business ,connective tissue tumor - Abstract
Familial risks of lung cancer are well-established, but whether lung cancer clusters with other discordant cancers is less certain, particularly beyond smoking-related sites, which may provide evidence on genetic contributions to lung cancer aetiology. We used a novel approach to search for familial associations in the Swedish Family-Cancer Database. This involved assessment of familial relative risk for cancer X in families with increasing numbers of lung cancer patients and, conversely, relative risks for lung cancer in families with increasing numbers of patients with cancers X. However, we lacked information on smoking. The total number of lung cancers in the database was 125 563. We applied stringent statistical criteria and found that seven discordant cancers were associated with lung cancer among family members, and six of these were known to be connected with smoking: oesophageal, upper aerodigestive tract, liver, cervical, kidney and urinary bladder cancers. A further novel finding was that cancer of unknown primary also associated with lung cancer. We also factored in histological evidence and found that anal and connective tissue cancers could be associated with lung cancer for reasons other than smoking. For endometrial and prostate cancers, suggestive negative associations with lung cancer were found. Although we lacked information on smoking it is prudent to conclude that practically all observed discordant associations of lung cancer were with cancers for which smoking is a risk factor., Among family members of lung cancer patients, 7 other cancers were found, all of which were smoking related http://ow.ly/ZLnt30csVfZ
- Published
- 2017
46. Autologous stem cell transplantation and stem cell mobilization kinetics in elderly patients with B cell non-Hodgkin lymphoma
- Author
-
Serkan Ocakci, Seckin Cagirgan, Leylagül Kaynar, Selda Kahraman, Mehmet Ali Erkurt, Neslihan Mandaci Şanli, Sibel Hacioglu, Kadir Ilkkilic, Ali Kaya, Mehmet Hilmi Dogu, Emre Tekgündüz, Fevzi Altuntaş, and Rafet Eren
- Subjects
Oncology ,Male ,autologous stem cell transplantation ,Transplantation Conditioning ,B-cell non-Hodgkin lymphoma ,medicine.medical_treatment ,retrospective study ,Mobilization ,morbidity ,Hematopoietic stem cell transplantation ,etoposide ,geriatric patient ,B cell non Hodgkin lymphoma ,granulocyte colony stimulating factor ,survival analysis ,0302 clinical medicine ,Autologous stem-cell transplantation ,immune system diseases ,cytarabine ,hemic and lymphatic diseases ,Medicine ,CD34 antigen ,cancer survival ,Univariate analysis ,clinical article ,B-Lymphocytes ,nonhodgkin lymphoma ,ifosfamide ,Standard treatment ,Lymphoma, Non-Hodgkin ,Hematopoietic Stem Cell Transplantation ,Hematology ,Hematopoietic Stem Cell Mobilization ,aged ,female ,030220 oncology & carcinogenesis ,carboplatin ,B-Cell Non-Hodgkin Lymphoma ,Female ,cyclophosphamide plus doxorubicin plus prednisolone plus rituximab plus vincristine ,medicine.medical_specialty ,overall survival ,mantle cell lymphoma ,Aged ,B-Lymphocytes/*metabolism ,Hematopoietic Stem Cell Mobilization/*methods ,Hematopoietic Stem Cell Transplantation/*methods ,Humans ,Lymphoma, Non-Hodgkin/mortality/pathology/*therapy ,Survival Analysis ,Transplantation Conditioning/*methods ,Transplantation, Autologous/*methods ,Transplantation, Autologous ,Article ,03 medical and health sciences ,follicular lymphoma ,Internal medicine ,cancer combination chemotherapy ,autologous hematopoietic stem cell transplantation ,cancer radiotherapy ,follow up ,human ,procedures ,Survival analysis ,Autologous hematopoietic stem cell ,autotransplantation ,carmustine ,B lymphocyte ,business.industry ,plerixafor ,treatment response ,medicine.disease ,mortality ,diffuse large B cell lymphoma ,Lymphoma ,melphalan ,stem cell mobilization ,Transplantation ,Elderly patients ,pathology ,transplantation ,business ,metabolism ,030215 immunology - Abstract
As known, the world population is aging and as the life span increases the number of advanced-age lymphomas also shows an upward trend. Autologous hematopoietic stem cell transplantation (HSCT) is the standard treatment modality in chemotherapy-sensitive relapsed or refractory aggressive lymphomas. Increased morbidity and mortality related to both the transplant itself and comorbid diseases can be observed in elderly lymphoma patients. Patients who are 65 years or older and underwent autologous HSCT with B-cell non-Hodgkin lymphoma were retrospectively included in our study. In terms of survival analysis, median follow-up was 34.5 months (8-159) while the overall survival (OS) was 58%. In the univariate analysis of prognostic data in OS, patients who were referred to transplantation with complete response had a statistically significant survival advantage (p=0.043). In terms of the effect of pre-transplant conditioning regimens on survival, BEAM regimen yielded better results, though not statistically significant. Age, number of chemotherapy cycles received before mobilization and radiation therapy had no significant effect on the CD34 (+) cell count in the final product (p = 0.492, 0.746 and 0.078 respectively). In conclusion, autologous HSCT is a practicable treatment modality that provides survival advantage in suitable advanced-age patients with a diagnosis of B-cell non-Hodgkin lymphoma. (C) 2017 Elsevier Ltd. All rights reserved.
- Published
- 2017
47. Lenfomada Atipik Prezentasyon; Sol Elde Siyanoz: Olgu Sunumu.
- Author
-
Özhasenekler, Ayhan, Arıtürk Atılgan, Zuhal, Bakır, Şule, Gökhan, Şervan, and Yılmaz, Fevzi
- Subjects
- *
LYMPHOMAS , *CYANOSIS , *MEDIASTINUM , *TRACHEA , *TOMOGRAPHY , *LYMPH nodes , *DRUG therapy - Abstract
A 17 year old female patient was admitted to the emergency service with complaints of cough, asthma, and cyanosis in the left hand. Expanding in the mediastinum, a rightward deviation of the trachea was specified in the posterior-anterior lung x-ray. In her thoracic computerised tomography, soft tissue density, rightward deviation of trachea, narrowing inwards from outside with the left major bronchus was observed and there were common lymph nodules on the upper section of the left trachea. These lymph nodes applied pressure on major vascular structures leading to the left arm. Primarily lymphoma was considered because she was a young patient. Diagnosis-based left axial and left nodule excision was carried out. Histopathologically, a non-Hodgkin lymphoma (NHL) was diagnosed. The patient was given chemotherapy. The cyanosis in the hand was healed after the mass decreased, thus decreasing pressure on vascular structures. Lymphoma, which is one of the mediastinal masses, is also considered with congenital cardiac illnesses such as pulmonary hypertension, improved Patent Ductus Arteriosis Eisenmenger Syndrome in young patients admitted to the emergency service with atypical complaints such as cyanosis in the left hand. [ABSTRACT FROM AUTHOR]
- Published
- 2011
- Full Text
- View/download PDF
48. Endobronchial ultrasound-guided transbronchial needle aspirate for diagnosis of anaplastic large cell lymphoma of unusual presentation: A case report.
- Author
-
Sua, Luz F., Arias, Daniela, Morales, Eliana I., Bravo, Juan C., Zúñiga-Restrepo, Valeria, and Fernández-Trujillo, Liliana
- Abstract
Anaplastic large cell lymphoma (ALCL) is a rare type of non-Hodgkin lymphoma (NHL) originated from mature post thymic T cells. They represent 1–3% of NHL. Different subtypes have been described: Anaplastic lymphoma kinase (ALK)-negative ALCL, ALK-positive ALCL and breast implant-associated ALCL. ALK-positive ALCL affects mainly the young and has better prognosis. We present a case report of an adult woman with AKL-positive ALCL, diagnosed by endobronchial ultrasound-guided transbronchial needle aspirate (EBUS-TBNA). A 59-year-old women with no history of breast implants, was admitted for a four-month low back pain. Initially, the patient was treated for a spondyloarthropathy, but due to persistence of the symptoms, a lumbosacral MRI was performed, showing changes in morphology and signal intensity in the vertebral body of L3, along with edema and a paravertebral collection that affected the left psoas muscle, suggesting granulomatous spondylodiscitis. Chest CT-scan showed mild left pleural effusion, subcarinal and right hiliar adenomegalies. An EBUS-TBNA with ROSE (rapid on-site evaluation) was performed showing positive findings for malignancy, suggestive of hematolymphoid neoplasia. Pathology analysis showed an AKL-positive ALCL. Additionally, a biopsy of paravertebral tissue biopsy was obtained, which was consistent with the nodal sample. Chemotherapy was initiated with the CHOP protocol: cyclophosphamide, hydroxydaunorubicin, vincristine sulfate and prednisone. EBUS-TBNA is a minimally invasive and safe technique for obtaining mediastinal samples. Collaboration with a cytopathologist trained to perform ROSE improves the diagnostic performance. [ABSTRACT FROM AUTHOR]
- Published
- 2019
- Full Text
- View/download PDF
49. Mutational status of EZH2 and CD79B hot spots in mature B-cell non-Hodgkin's lymphomas: Novel CD79B variations have been revealed
- Author
-
Çetin Gökhan Ozan, Barış, İkbal Cansu, Caner, Vildan, Sarıkepe, Bilge, Şen Türk, Nilay, Tepeli, Emre, Hacıoglu, Sibel, Sarı , Hakan İsmail, Bagcı, Gülseren, and Keskin, Ali
- Subjects
mutational analysis ,single nucleotide variation ,Male ,Lymphoma, B-Cell ,genetic association ,very elderly ,transcription factor EZH2 ,DNA sequence ,CD79B ,Antigens, CD79 ,gene frequency ,high risk patient ,Article ,Cohort Studies ,middle aged ,Humans ,EZH2 gene ,controlled study ,Enhancer of Zeste Homolog 2 Protein ,genetics ,EZH2 ,human ,gene mutation ,CD79B protein, human ,Mature B-cell non-Hodgkin lymphoma ,Aged, 80 and over ,clinical article ,nonhodgkin lymphoma ,cancer staging ,CD79 antigen ,adult ,CD79B gene ,Genetic Variation ,cohort analysis ,human tissue ,B cell lymphoma ,aged ,female ,Mutation ,EZH2 protein, human ,CD79b antigen ,pathology ,carcinogenesis - Abstract
OBJECTIVE: We aimed to determine the hot spot mutational frequencies of Enhancer of Zeste homolog 2 (EZH2) and cluster of differentiation 79B (CD79B) genes in a cohort of mature B-cell non-Hodgkin's lymphomas. PATIENTS AND METHODS: DNA samples from formalin-fixed and paraffin embedded (FFPE) tissues from a total of 37 patients with mature B-cell non-Hodgkin lymphomas were included in the study. Molecular genetic analysis was performed by direct sequencing of the DNA samples. RESULTS: We analyzed formaldehyde fixed-paraffin embedded (FFPE) tumor tissue samples from 17 female and 20 male patients with a median age of 63.7 years at the time of diagnosis. None of the patients had previously reported hot spot mutations in EZH2 and CD79B, but previously unreported single nucleotide variations of CD79B were present in nine patients. rs779833118 was the most frequent variation (7/37 patients, 18.9%). A non-synonymous variation rs757407417, which could have a potentially damaging outcome, was detected in two patients. CONCLUSIONS: None of the patients had well-known hot spot mutations in EZH2 and CD79B. However, we detected novel CD79B variations in mature B-cell non-Hodgkin's lymphoma patients. © 2016, Verduci Editore. All rights reserved.
- Published
- 2016
50. Use Of Complementary and Alternative Medicine in Children With Cancer: Effect on Survival
- Author
-
Metin Demirkaya, Betül Sevinir, Yasin Karali, Uludağ Üniversitesi/Tıp Fakültesi/Pediatri Anabilim Dalı., Karalı, Yasin, Demirkaya, Metin, Sevinir, Betül, C-7392-2019, and AAH-1570-2021
- Subjects
Male ,Survival rate ,Alternative medicine ,Turkey ,Pediatrics ,Infant, newborn ,Neuroblastoma ,Neoplasms ,Medicine ,Child ,Children ,Nephroblastoma ,Cancer ,Osteosarcoma ,Soft tissue sarcoma ,Traditional medicine ,Urtica dioica ,Honey ,Hematology ,Dietary supplements ,Long term survival ,Plants, medicinal ,Oncology ,Nonhodgkin lymphoma ,Female ,Complementary and Alternative Medicine ,Homeopathy ,Acupuncture ,Human ,Adult ,medicine.medical_specialty ,Hodgkin disease ,Child, preschool ,Adolescent ,Disease-free survival ,education ,Dietary supplement ,Alternative treatment ,MEDLINE ,Follow-up studies ,Major clinical study ,Pediatric oncology patients ,Diet supplementation ,Article ,Education ,Internal medicine ,Humans ,Family ,Socioeconomic status ,Demography ,business.industry ,Infant ,Follow up ,Newborn ,medicine.disease ,Complementary therapies ,Cancer survival ,Clinical trial ,Preschool child ,Physician ,Socioeconomics ,Therapies ,Pediatrics, Perinatology and Child Health ,School child ,business ,Complementary medicine - Abstract
The objective of the present study was to determine the type, frequency, the reason why complementary and alternative medicine (CAM) treatments are used, the factors related with their use, and the effects of CAM usage on long-term survival. Families of a total of 120 children with cancer between 0-18 years of age, including 50 (41.7%) girls and 70 (58.3%) boys, participated in our study. The authors found that 88 patients (73.3%) used at least one CAM method, the most common (95.5%) of which was biologically based therapies. Most frequently used biologically based therapies were dietary supplements and herbal products. The most commonly used dietary supplement or herbal product was honey (43.2%) or stinging nettle (43.2%), respectively. We found that patients used such CAM methods as complementary to, but not instead of, conventional therapy. Sixty-nine out of 88 patient families (78.4%) shared the CAM method they used with their physicians. No statistically significant relation was found between socioeconomic, sociodemographic, or other factors or items and CAM use. The mean follow-up period of the CAM users and nonusers groups was 79.4 +/- 36.7 (21.3-217.9) and 90.9 +/- 50.3 (27.4-193.7) months, respectively. Five-year survival rates for CAM users and nonusers were found as 81.5% and 86.5%, respectively (P > .05). In conclusion, families of children with cancer use complementary and alternative treatment frequently. They do not attempt to replace conventional treatment with CAM. Higher rates of CAM use was found in families with higher educational level. CAM usage did not affect the long-term survival.
- Published
- 2012
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.